Chapter review

Must know

• Table: Alcohol Withdrawal StagesAlcohol withdrawal onset occurs within 6 to 12 hours after the last drink, peaks at 24 to 48 hours, and subsides over 5 to 7 days.

  • Alcohol withdrawal onset occurs within 6 to 12 hours after the last drink, peaks at 24 to 48 hours, and subsides over 5 to 7 days.
  • Stage 1 mild withdrawal develops at 6 to 12 hours, presenting with tremors, tachycardia, hypertension, diaphoresis, insomnia, and mild anxiety.
  • Stage 2 moderate withdrawal develops at 12 to 24 hours, adding motor agitation, pronounced autonomic instability, and transient visual, tactile, or auditory hallucinations with an intact sensorium.
  • Stage 3 withdrawal seizures peak at 24 to 48 hours as generalized tonic-clonic events; up to 30% of untreated seizure cases progress to delirium tremens.
  • Stage 4 severe withdrawal or delirium tremens emerges at 48 to 96 hours, causing severe confusion, fluctuating orientation, autonomic storm (fever, profuse sweating, extreme tachycardia), and carries up to a 15% mortality rate if untreated.
  • A CIWA-Ar score over 15 indicates severe withdrawal requiring active pharmacotherapy, while a score under 8 to 10 requires supportive care without medications.
• Spoken Teaching: Stages and TimelinesLong-acting benzodiazepines like chlordiazepoxide and diazepam are first-line agents for alcohol withdrawal detoxification because their active hepatic metabolites provide a smooth auto-taper. However, in patients with severe hepatic impairment, advanced cirrhosis, or elderly ind

  • Alcohol withdrawal represents a continuum of central nervous system hyperexcitability caused by abrupt cessation of alcohol's chronic GABA enhancement and NMDA glutamate suppression.
  • When comparing the four distinct stages across time, autonomic hyperactivity links every phase, while neuro-psychiatric severity escalates sharply as time progresses.
  • In Stage 1 (mild withdrawal occurring 6 to 12 hours post-cessation) and Stage 2 (moderate withdrawal occurring 12 to 24 hours post-cessation), patients maintain intact sensorium and orientation.
  • What separates Stage 2 from Stage 1 is the onset of motor agitation and short-lived perceptual disturbances or hallucinations, whereas Stage 1 features isolated mild tremors, diaphoresis, tachycardia, and anxiety.

  Board trap. Do not assume that a low CIWA score or a history of major depression determines treatment setting. A past history of delirium tremens or alcohol withdrawal seizures is the single most prominent risk factor favoring immediate medical hospitalization rather than outpatient detoxifi

  Safety. Always administer thiamine (Vitamin B1) prior to IV glucose administration in patients with suspected or actual alcohol use disorder. Glucose loading without thiamine rapidly consumes remaining thiamine coenzymes during pyruvate oxidation, triggering or worsening acute Wernicke's

• Signs of Delirium Tremens (DTs)Alcohol withdrawal timeline: Autonomic hyperactivity and hand tremors begin within 6 to 24 hours of the last drink, withdrawal seizures peak between 12 and 48 hours, and delirium tremens typically emerges between 48 and 96 hours.

  • Alcohol withdrawal timeline: Autonomic hyperactivity and hand tremors begin within 6 to 24 hours of the last drink, withdrawal seizures peak between 12 and 48 hours, and delirium tremens typically emerges between 48 and 96 hours.
  • Signs of delirium tremens: Delirium tremens is a life-threatening medical emergency characterized by profound delirium, disorientation, severe autonomic instability, marked tachycardia, fever, hypertension, diaphoresis, agitation, and visual or tactile hallucinations.
  • Primary risk factor for hospitalization: A prior history of delirium tremens is the single most significant predictor of recurrent severe withdrawal and dictates immediate inpatient hospital admission.
  • Clinical Institute Withdrawal Assessment: The CIWA-Ar scale evaluates 10 withdrawal domains on a 0 to 67 scale, where a score of 15 or greater indicates severe withdrawal requiring aggressive medication management.
  • First-line pharmacotherapy: Benzodiazepines such as lorazepam, chlordiazepoxide, or diazepam are the gold standard to suppress central nervous system irritability and prevent seizures or DTs.
  • Wernicke-Korsakoff prevention: Thiamine (vitamin B1) at 100 mg to 250 mg daily must always be administered prior to intravenous glucose to prevent acute Wernicke encephalopathy and chronic Korsakoff psychosis.
• Progression of Alcohol WithdrawalMild withdrawal occurs within 6 to 24 hours and presents with anxiety, insomnia, mild tremors, diaphoresis, palpitations, and gastrointestinal upset.

  • Mild withdrawal occurs within 6 to 24 hours and presents with anxiety, insomnia, mild tremors, diaphoresis, palpitations, and gastrointestinal upset.
  • Withdrawal seizures occur within 12 to 48 hours and present as brief, generalized tonic-clonic events.
  • Alcoholic hallucinosis occurs within 12 to 24 hours and presents with visual, auditory, or tactile hallucinations while orientation remains intact.
  • Delirium tremens occurs within 48 to 96 hours and presents with clouding of consciousness, global disorientation, severe psychomotor agitation, and autonomic hyperactivity.
• Assessment and Scoring with CIWA-ArEvaluated domains include nausea and vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation.

  • Evaluated domains include nausea and vomiting, tremor, paroxysmal sweats, anxiety, agitation, tactile disturbances, auditory disturbances, visual disturbances, headache, and orientation.
  • Scores under 8 reflect mild withdrawal manageable with supportive care.
  • Scores between 8 and 14 reflect moderate withdrawal where symptom-triggered medication is initiated.
  • Scores of 15 or higher indicate severe withdrawal with a high risk for delirium tremens, requiring inpatient admission and protocol-driven benzodiazepine administration.
• Clinical Management and Medical SafeguardsBenzodiazepines are the first-line drug class for managing acute alcohol withdrawal and preventing delirium tremens. Long-acting agents like chlordiazepoxide and diazepam provide a smooth tapering effect in patients with healthy hepatic function. Short-acting agents lacking activ

  • Delirium tremens carries a mortality rate up to 5 percent due to cardiovascular collapse, hyperthermia, electrolyte derangements, or respiratory failure. Continuous vital sign monitoring, parenteral fluids, and continuous cardiac monitoring in an inpatient unit are required.
  • Another frequent trap presents a patient with a low current CIWA-Ar score who has a documented past history of delirium tremens. A prior history of DTs overrides a low initial score and mandates inpatient detoxification rather than outpatient management.

  Board trap. Test writers often construct stems where a malnourished or intoxicated patient receives intravenous glucose before thiamine. Administering glucose without thiamine depletes remaining thiamine cofactors during glycolysis, directly precipitating Wernicke encephalopathy. Always give

  Safety. Delirium tremens carries a mortality rate up to 5 percent due to cardiovascular collapse, hyperthermia, electrolyte derangements, or respiratory failure. Continuous vital sign monitoring, parenteral fluids, and continuous cardiac monitoring in an inpatient unit are required.

• Alcohol Withdrawal Seizures vs Delirium TremensThink: Seizures occur early with clear sensorium, whereas DTs occur late with severe delirium.

  • Think: Seizures occur early with clear sensorium, whereas DTs occur late with severe delirium.
  • Onset timeline: Seizures peak at 12 to 48 hours post-cessation. DTs peak at 48 to 96 hours post-cessation.
  • Clinical presentation: Seizures are brief, self-limiting generalized tonic-clonic episodes without persistent confusion once postictal. DTs present with sustained clouding of consciousness, disorientation, terrifying hallucinations, and fluctuating vital signs.
  • Setting priority: Seizures require immediate acute medical evaluation, while DTs require continuous inpatient or intensive care monitoring.
• Wernicke Encephalopathy vs Korsakoff PsychosisThink: Wernicke is acute and reversible, whereas Korsakoff is chronic and irreversible.

  • Think: Wernicke is acute and reversible, whereas Korsakoff is chronic and irreversible.
  • Wernicke presentation: Acute triad of delirium, gait ataxia, and oculomotor dysfunction such as nystagmus or ophthalmoplegia.
  • Korsakoff presentation: Chronic neurocognitive disorder marked by severe anterograde and retrograde amnesia with confabulation.
  • Diagnostic logic: High-dose thiamine reverses Wernicke signs but cannot reverse established Korsakoff structural damage in the mammillary bodies and thalamus.
• Table: Overview — Stimulants and OpioidsStimulant intoxication presents with sympathetic hyperarousal including tachycardia (resting heart rate up to 140 beats per minute or higher), severe hypertension (such as 180/115 mmHg), dilated pupils (mydriasis), muscle weakness, diaphoresis, and acute paranoia or psychosis.

  • Stimulant intoxication presents with sympathetic hyperarousal including tachycardia (resting heart rate up to 140 beats per minute or higher), severe hypertension (such as 180/115 mmHg), dilated pupils (mydriasis), muscle weakness, diaphoresis, and acute paranoia or psychosis.
  • Stimulant withdrawal features a severe mood crash characterized by depressed mood, profound fatigue, vivid unpleasant dreams, psychomotor agitation or retardation, and increased appetite.
  • Opioid intoxication presents with classic central nervous system depression characterized by pupillary miosis (pinpoint pupils), respiratory depression, bradycardia, hypotension, hypothermia, and lethargy, whereas acute overdose is emergently reversed using naloxone.
  • First-line non-opioid symptom management for opioid withdrawal targets specific organ systems using clonidine for autonomic hyperactivity, ondansetron for nausea, loperamide for diarrhea, NSAIDs for body aches, and trazodone for insomnia.
  • Contingency contracting, which utilizes tangible rewards such as gift cards for verified negative urine drug screens, is an evidence-based behavioral intervention that is especially effective for methamphetamine use disorder.
• Pupil Findings and Autonomic ToneStimulants (such as dextroamphetamine, amphetamine, methamphetamine, methylphenidate, and cocaine) stimulate sympathetic pathways, causing dilated pupils (mydriasis), tachycardia, elevated blood pressure, and diaphoresis during intoxication.

  • Stimulants (such as dextroamphetamine, amphetamine, methamphetamine, methylphenidate, and cocaine) stimulate sympathetic pathways, causing dilated pupils (mydriasis), tachycardia, elevated blood pressure, and diaphoresis during intoxication.
  • Opioids (such as heroin, morphine, oxycodone, hydrocodone, fentanyl, and methadone) suppress central autonomic tone, causing pinpoint pupils (miosis), bradycardia, hypotension, and respiratory depression during intoxication.
  • Pupillary reversal in withdrawal: Pupils constrict or remain normal during stimulant withdrawal, whereas pupils dilate (mydriasis) accompanied by rhinorrhea, lacrimation, piloerection (gooseflesh), and yawning during opioid withdrawal.
• Behavioral and Pharmacotherapy StrategiesOpioid Use Disorder: Managed with medication-assisted treatment (MAT). Methadone acts as a full mu-opioid agonist, buprenorphine acts as a partial mu-opioid agonist, and naltrexone acts as an opioid antagonist to block euphoria and reduce cravings.

  • Opioid Use Disorder: Managed with medication-assisted treatment (MAT). Methadone acts as a full mu-opioid agonist, buprenorphine acts as a partial mu-opioid agonist, and naltrexone acts as an opioid antagonist to block euphoria and reduce cravings.
• Board Exam SignpostsFor non-opioid management of autonomic opioid withdrawal symptoms, clonidine is the first-line choice to suppress sympathetic overactivity.

  • For non-opioid management of autonomic opioid withdrawal symptoms, clonidine is the first-line choice to suppress sympathetic overactivity.
  • For opioid overdose with respiratory depression, naloxone is the immediate first-line emergency reversal agent.
  • Naltrexone must never be administered to a patient who is actively using opioids or who has scheduled elective surgery or dental procedures requiring opioid analgesics within the upcoming month, as it will precipitate severe, immediate opioid withdrawal.
  • Naltrexone is also contraindicated in patients with acute hepatitis or acute liver failure.
  • Stimulant intoxication can trigger life-threatening hypertensive crises, myocardial infarction, lethal cardiac arrhythmias, and hyperthermia.
  • Test writers often confuse naltrexone (a long-acting oral or IM opioid antagonist used for cravings in alcohol and opioid maintenance) with naloxone (a short-acting emergency antagonist used for acute opioid overdose reversal).
• Table: Overview — Cannabis and HallucinogensCannabis metabolites are lipophilic and remain detectable in urine for up to 1 month in regular users smoking 2 to 3 days per week.

  • Cannabis metabolites are lipophilic and remain detectable in urine for up to 1 month in regular users smoking 2 to 3 days per week.
  • Cannabis use in adolescents and young adults with underlying psychiatric vulnerability can precipitate or exacerbate schizophrenia and psychotic symptoms.
  • Therapeutic applications for THC include nausea, chronic pain, HIV or AIDS cachexia, cancer, glaucoma, multiple sclerosis, and epilepsy.
  • Cannabis tolerance develops with regular use, but physical dependence is low. Withdrawal manifests as irritability, restlessness, insomnia, anorexia, and mild nausea.
  • Hallucinogens include naturally occurring psilocybin and mescaline, alongside synthetic agents such as LSD, PCP, MDMA, and ketamine.
  • Hallucinogens alter serotonin and glutamate neurotransmission, producing profound perceptual distortions, synesthesias, and depersonalization without causing a physical withdrawal syndrome.
• SignpostsIntoxication management for cannabis or hallucinogens focuses on supportive care, a calm low-stimulation environment, physical safety, and symptom control.

  • Cannabis use in vulnerable adolescents and young adults significantly increases the risk of unmasking or worsening schizophrenia and psychotic spectrum disorders.
  • Confusing urine screening elimination windows. Single use clears rapidly, but regular use 2 to 3 days per week stores THC in adipose tissue, causing positive urine screens for up to 1 month.
  • Intoxication management for cannabis or hallucinogens focuses on supportive care, a calm low-stimulation environment, physical safety, and symptom control.

  Board trap. Confusing urine screening elimination windows. Single use clears rapidly, but regular use 2 to 3 days per week stores THC in adipose tissue, causing positive urine screens for up to 1 month.

  Safety. Cannabis use in vulnerable adolescents and young adults significantly increases the risk of unmasking or worsening schizophrenia and psychotic spectrum disorders.

• Cannabinoids (Cannabis)Neuropharmacology and Desired Effects: THC acts on central cannabinoid receptors. Desired effects include euphoria, relaxation, heightened sensory perception, and appetite stimulation.

  • Neuropharmacology and Desired Effects: THC acts on central cannabinoid receptors. Desired effects include euphoria, relaxation, heightened sensory perception, and appetite stimulation.
  • Approved and Medical Indications: Medical cannabis serves patients with nausea, chronic pain, HIV or AIDS cachexia, cancer, glaucoma, multiple sclerosis spasticity, and epilepsy.
  • Adverse Effects and Risks: Heavy chronic use is linked to chronic respiratory conditions, lung disease, cerebral structural alterations, executive function deficits, and heightened seizure susceptibility.
  • Dependency and Withdrawal Profile: Tolerance develops over time. True physical dependence is minimal. Withdrawal features mild irritability, restlessness, insomnia, anorexia, and mild nausea.
  • Urinary Elimination Timeline: Regular consumption of 2 to 3 days per week extends urine metabolite excretion up to 1 month.
• Hallucinogens (Psychedelics)Naturally Occurring and Synthetic Classes: Naturally derived agents include psilocybin from mushrooms and mescaline from peyote cactus. Synthetic and pharmaceutical agents include LSD, PCP, MDMA, and ketamine.

  • Naturally Occurring and Synthetic Classes: Naturally derived agents include psilocybin from mushrooms and mescaline from peyote cactus. Synthetic and pharmaceutical agents include LSD, PCP, MDMA, and ketamine.
  • Clinical Presentation of Intoxication: Hallucinogenic intoxication features visual illusions, synesthesias, derealization, depersonalization, pupillary dilation, tachycardia, sweating, tremors, and incoordination.
  • Dependence and Withdrawal Mechanics: Hallucinogens produce rapid psychological tolerance and psychological dependence. They do not produce physical dependence or a physical withdrawal syndrome.
  • Therapeutic Integration: Clinical application of ketamine and psilocybin includes ketamine-assisted psychotherapy for treatment-resistant depression, PTSD, and alcohol use disorder. States like Oregon have legalized psilocybin for regulated therapeutic environments.
• Opioid Intoxication SignsOpioid intoxication presents with the core clinical triad of pupillary constriction (pinpoint pupils or miosis), respiratory depression (bradypnea or shallow breathing), and central nervous system depression (drowsiness, lethargy, stupor, or coma).

  • Opioid intoxication presents with the core clinical triad of pupillary constriction (pinpoint pupils or miosis), respiratory depression (bradypnea or shallow breathing), and central nervous system depression (drowsiness, lethargy, stupor, or coma).
  • Naloxone (Narcan) nasal spray or intravenous administration is the first-line emergency treatment for acute opioid overdose with respiratory depression to rapidly displace opioids from mu-opioid receptors and restore breathing.
  • Diagnostic criteria for substance use disorder require 2 or more of 11 criteria within a 12-month period, categorized by severity as mild (2 to 3 criteria), moderate (4 to 5 criteria), or severe (6 or more criteria) using the mnemonic tempted with cocaine, Scotch, and rum.
• Opioid Intoxication Signs and Clinical ManagementOpioid intoxication occurs when exogenous opioid agonists bind central and peripheral mu-opioid receptors, down-regulating central nervous system arousal and autonomic output.

  • Opioid intoxication occurs when exogenous opioid agonists bind central and peripheral mu-opioid receptors, down-regulating central nervous system arousal and autonomic output.
• Core Clinical PresentationOcular Findings: Pupillary constriction (pinpoint pupils or miosis) is the hallmark physical finding on board examination.

  • Ocular Findings: Pupillary constriction (pinpoint pupils or miosis) is the hallmark physical finding on board examination.
  • Respiratory Findings: Respiratory depression with reduced respiratory rate, hypoventilation, and shallow breathing.
  • Neurologic Findings: Sedation, slurred speech, psychomotor retardation, stupor, and unresponsiveness.
  • Autonomic and Gastrointestinal Findings: Hypotension, bradycardia, hypothermia, decreased bowel sounds, and severe constipation.
  • First-line intervention for acute opioid intoxication complicated by respiratory depression is immediate administration of naloxone (Narcan) via intranasal or parenteral routes to restore airway patency and spontaneous ventilation.

  Board trap. Do not confuse naloxone with naltrexone. Naloxone is a short-acting emergency antagonist used for acute overdose reversal. Naltrexone is a long-acting antagonist used for long-term relapse prevention in alcohol use disorder and opioid use disorder. Administering naltrexone to a p

  Safety. When administering naloxone, monitor the patient continuously because the elimination half-life of naloxone (30 to 90 minutes) is substantially shorter than that of long-acting opioids like methadone or sustained-release morphine. Respiratory depression can recur as naloxone wear

• Opioid Intoxication vs. Stimulant IntoxicationThink Opioid Intoxication when: Stem describes pinpoint pupils (pupillary constriction), respiratory depression, bradycardia, hypotension, and central nervous system lethargy.

  • Think Opioid Intoxication when: Stem describes pinpoint pupils (pupillary constriction), respiratory depression, bradycardia, hypotension, and central nervous system lethargy.
  • Think Stimulant Intoxication when: Stem describes dilated pupils (pupillary dilation or mydriasis), severe hypertension (e.g., 180 over 115 mmHg), tachycardia (e.g., 140 beats per minute), muscle weakness, and cardiac hyperarousal.
  • Priority difference: Opioid intoxication requires immediate airway protection and naloxone reversal; stimulant intoxication requires cardiovascular monitoring and cooling or sedation for adrenergic crisis.
• Opioid Intoxication vs. Opioid WithdrawalThink Opioid Intoxication when: Stem reveals miosis, drowsiness, hypoventilation, decreased bowel sounds, and bradycardia.

  • Think Opioid Intoxication when: Stem reveals miosis, drowsiness, hypoventilation, decreased bowel sounds, and bradycardia.
  • Think Opioid Withdrawal when: Stem reveals mydriasis, lacrimation, rhinorrhea, yawning, piloerection (gooseflesh), severe abdominal cramping, diarrhea, and joint pain (arthralgia).
  • Board distinction: Intoxication slows all systems down; withdrawal accelerates autonomic output up.
• Stimulant Intoxication SignsImmediate management prioritizes airway protection, cardiac monitoring, cooling measures for hyperthermia, and benzodiazepines to control agitation and hypertension.

  • Stimulant intoxication presents with sympathomimetic hyperarousal, including tachycardia (heart rate exceeding 100 to 140 beats per minute), severe hypertension (systolic blood pressure over 180 mmHg), and pupillary dilation.
  • Central nervous system stimulants tested on boards include dextroamphetamine, amphetamine salts, methamphetamine, methylphenidate, and cocaine.
  • Physical signs of acute toxicity include muscle weakness, diaphoresis, chills, nausea, vomiting, chest pain, cardiac arrhythmias, confusion, seizures, and potential sudden cardiac death.
  • Psychological signs include euphoria, hypervigilance, agitation, grandiosity, impaired judgment, paranoia, and tactile hallucinations such as formication.
  • Peak physical and autonomic effects after oral ingestion typically manifest within 1 to 2 hours post-ingestion.
  • Severe stimulant toxicity can trigger lethal hypertensive crisis, acute myocardial infarction, aortic dissection, hyperthermia, and status epilepticus.

  Board trap. Do not confuse pupillary dilation seen in stimulant intoxication with the pupillary constriction seen in opioid toxicity.

  Safety. Severe stimulant toxicity can trigger lethal hypertensive crisis, acute myocardial infarction, aortic dissection, hyperthermia, and status epilepticus.

• Quick AnswerDextroamphetamine is the correct choice because acute stimulant intoxication presents with severe sympathomimetic signs including marked tachycardia, severe hypertension, pupillary dilation, and muscle weakness.

  • Dextroamphetamine is the correct choice because acute stimulant intoxication presents with severe sympathomimetic signs including marked tachycardia, severe hypertension, pupillary dilation, and muscle weakness.
• B) DextroamphetamineA: Cannabis intoxication typically produces conjunctival injection, increased appetite, dry mouth, and mild tachycardia, but does not cause severe hypertension of 180 over 115 mmHg, marked pupillary dilation, or muscle weakness.

  • A: Cannabis intoxication typically produces conjunctival injection, increased appetite, dry mouth, and mild tachycardia, but does not cause severe hypertension of 180 over 115 mmHg, marked pupillary dilation, or muscle weakness.
  • C: Diazepam is a central nervous system depressant whose intoxication causes sedation, ataxia, slurred speech, and respiratory depression, rather than autonomic hyperarousal, tachycardia, and hypertension.
  • D: Oxycodone is an opioid agonist whose toxicity manifests with pupillary constriction, respiratory depression, hypotension, and bradycardia, which is the exact physiological opposite of this clinical presentation.
• Mesolimbic Dopamine CircuitThe mesolimbic dopamine circuit connects the ventral tegmental area (dopaminergic cell bodies) to the ventral striatum (pleasure and reward target).

  • The mesolimbic dopamine circuit connects the ventral tegmental area (dopaminergic cell bodies) to the ventral striatum (pleasure and reward target).
  • Natural rewards like food, sex, and social connection trigger baseline dopamine release, whereas drugs of abuse like cocaine or amphetamines cause exaggerated dopamine surges that alter synaptic communication.
  • Diagnostic criteria for substance use disorder require 2 or more of 11 criteria within a 12-month period, categorized as mild (2 to 3 symptoms), moderate (4 to 5 symptoms), or severe (6 or more symptoms).
  • Neuroplastic changes in the reward circuitry persist beyond acute detoxification, driving chronic cravings and high relapse risk long after physical withdrawal resolves.
  • The amygdala conditions emotional learning to drug cues, while the hippocampus stores specific memories of the drug experience.
  • Executive choice and impulse control reside in the medial prefrontal cortex, anterior cingulate cortex, and orbitofrontal cortex, which become impaired as addiction progresses.
• Anatomical Core of the Reward PathwayVentral tegmental area: Houses the cell bodies of dopaminergic neurons. It acts as the origin point of the mesolimbic pathway, projecting axons directly to forebrain structures.

  • Ventral tegmental area: Houses the cell bodies of dopaminergic neurons. It acts as the origin point of the mesolimbic pathway, projecting axons directly to forebrain structures.
  • Ventral striatum: Includes the nucleus accumbens, which serves as the primary dopaminergic target of projections from the ventral tegmental area. This region acts as the pleasure center, translating dopamine release into the sensation of reward.
• Memory, Emotion, and Physiologic IntegrationAmygdala: Responsible for conditioned learning and attaching emotional significance to experiences. It pairs drug consumption with environmental cues, generating emotional triggers when exposed to sights or places associated with past use.

  • Amygdala: Responsible for conditioned learning and attaching emotional significance to experiences. It pairs drug consumption with environmental cues, generating emotional triggers when exposed to sights or places associated with past use.
  • Hippocampus: Formulates and stores explicit declarative memories of drug experiences. It records the context, environment, and specific details of substance administration.
  • Hypothalamus: Coordinates reward signaling with homeostatic bodily drives, integrating basic physiological needs such as hunger and thirst with reward seeking.
• Executive Control and Modulatory Neurotransmitter SystemsFrontal regions: Comprising the medial prefrontal cortex, anterior cingulate cortex, and orbitofrontal cortex. These structures oversee executive function, valuation, impulse inhibition, and conscious choice.

  • Frontal regions: Comprising the medial prefrontal cortex, anterior cingulate cortex, and orbitofrontal cortex. These structures oversee executive function, valuation, impulse inhibition, and conscious choice.
  • Locus coeruleus: The principal origin of noradrenergic neurons in the brain. It regulates autonomic arousal, vigilance, and physical activation.
  • Dorsal raphe nucleus: The primary site of serotonergic cell bodies. It modulates mood regulation, impulse control, and emotional activation across the circuit.
• Pathophysiology of Substance DysregulationFirst-line clinical understanding: Recognize that chronic substance exposure causes long-term structural and functional remodeling of brain circuits. These neuroadaptations persist long after physical detoxification is complete.

  • First-line clinical understanding: Recognize that chronic substance exposure causes long-term structural and functional remodeling of brain circuits. These neuroadaptations persist long after physical detoxification is complete.
  • Neurological rewiring impairs frontal executive inhibition, rendering patients vulnerable to intense cravings when exposed to environmental cues processed by the amygdala and hippocampus.
  • Assuming that completing acute withdrawal or detoxification restores normal reward circuitry. Cravings and relapse risk remain high because circuit dysregulation persists for months to years.

  Board trap. Assuming that completing acute withdrawal or detoxification restores normal reward circuitry. Cravings and relapse risk remain high because circuit dysregulation persists for months to years.

  Safety. Neurological rewiring impairs frontal executive inhibition, rendering patients vulnerable to intense cravings when exposed to environmental cues processed by the amygdala and hippocampus.

• Stacked Contrast: Natural Rewards vs. Drugs of AbuseStimulus: Food, sex, social connection, music.

  • Stimulus: Food, sex, social connection, music.
  • Dopamine release: Moderate, physiological, transient surge.
  • Circuit impact: Preserves normal synaptic signaling and executive control in frontal regions.
• Drugs of AbuseStimulus: Cocaine, amphetamines, opioids, alcohol.

  • Stimulus: Cocaine, amphetamines, opioids, alcohol.
  • Dopamine release: Exaggerated, artificial, pathological flood into the ventral striatum.
  • Circuit impact: Alters synaptic communication, downregulates receptors, weakens frontal executive control, and embeds persistent drug memories.
• Stacked Contrast: Amygdala vs. Hippocampus in RewardPrimary function: Attaches emotional feeling and conditioned learning to drug use.

  • Primary function: Attaches emotional feeling and conditioned learning to drug use.
  • Board clue: Triggered by emotional states or environmental cues that spark sudden cravings.
  • Primary function: Stores factual memory of the drug experience, location, and context.
  • Board clue: Remembers the specific steps, places, and details surrounding prior substance use.
• Key ClueA. Cerebellum regulates motor coordination, balance, and cognitive timing rather than emotional conditioning.

  • A. Cerebellum regulates motor coordination, balance, and cognitive timing rather than emotional conditioning.
  • B. Ventral striatum contains the nucleus accumbens, which serves as the primary dopaminergic pleasure target from the ventral tegmental area, rather than the emotional conditioning center.
  • C. Hypothalamus coordinates autonomic and neuroendocrine functions with basic physiologic drives like hunger and thirst, not emotional conditioned learning.
• Cognitive and Emotional Control CentersThe mesolimbic dopamine circuit serves as the primary reward pathway activated by natural rewards such as food, sex, and social connection, but drugs of abuse cause exaggerated dopamine surges that alter synaptic communication.

  • The mesolimbic dopamine circuit serves as the primary reward pathway activated by natural rewards such as food, sex, and social connection, but drugs of abuse cause exaggerated dopamine surges that alter synaptic communication.
  • Medial prefrontal cortex, anterior cingulate cortex, and orbitofrontal cortex provide executive control, decision-making, and choice evaluation, which become chronically dysregulated in substance use disorders.
  • Amygdala connects drug experiences with emotional valence and conditioned learning, driving cue-induced cravings.
  • Hippocampus establishes long-term contextual memories of drug experiences that persist after detoxification.
  • Hypothalamus coordinates brain reward signaling with physiological bodily needs.
  • Locus coeruleus serves as the primary source of norepinephrine neurons regulating arousal, while the dorsal raphe nucleus supplies serotonin neurons modulating mood and activation.
• Executive Control and Decision-MakingFrontal cortical structures include the medial prefrontal cortex, anterior cingulate cortex, and orbitofrontal cortex.

  • Frontal cortical structures include the medial prefrontal cortex, anterior cingulate cortex, and orbitofrontal cortex.
  • These frontal regions govern executive control, goal-directed choices, risk assessment, and behavioral inhibition.
  • Chronic substance use causes underlying changes in frontal circuitry that persist beyond physical detoxification, especially in severe cases.
• Emotional Processing and Conditioned LearningAmygdala connects drug-using experiences with emotional responses and conditioned learning. It attaches emotional weight to environmental triggers and cues.

  • Amygdala connects drug-using experiences with emotional responses and conditioned learning. It attaches emotional weight to environmental triggers and cues.
  • Hypothalamus integrates reward circuitry signaling with physiological bodily needs and endocrine regulation.
• Neuromodulatory and Arousal CentersLocus coeruleus contains norepinephrine cell bodies that regulate autonomic arousal, vigilance, and stress responses during intoxication and withdrawal.

  • Locus coeruleus contains norepinephrine cell bodies that regulate autonomic arousal, vigilance, and stress responses during intoxication and withdrawal.
  • Dorsal raphe nucleus contains serotonin cell bodies that modulate mood, impulse control, and emotional activation across the reward circuit.
• Reward and Memory IntegrationVentral tegmental area houses dopaminergic cell bodies that project directly to the ventral striatum to signal reward.

  • Ventral tegmental area houses dopaminergic cell bodies that project directly to the ventral striatum to signal reward.
  • Hippocampus stores declarative and contextual memories of drug use, reinforcing repetition of rewarding behaviors.
• Clinical Signposts and Board StrategyCombine pharmacotherapy such as naltrexone or acamprosate for alcohol use disorder with evidence-based psychosocial interventions including motivational interviewing, cognitive behavioral therapy, and contingency contracting to address both neurobiological dysregulation and cogni

  • Underlying changes in brain reward circuitry persist beyond physical detoxification. Patients remain at high risk for cue-induced relapse even after years of sobriety when exposed to major life stressors or environmental triggers.
  • Do not confuse the role of the amygdala with the hippocampus. The amygdala links experiences to emotional valence and conditioned learning, while the hippocampus stores explicit drug memories. On board exams, conditioned emotional learning points directly to the amygdala.

  Board trap. Do not confuse the role of the amygdala with the hippocampus. The amygdala links experiences to emotional valence and conditioned learning, while the hippocampus stores explicit drug memories. On board exams, conditioned emotional learning points directly to the amygdala.

  Safety. Underlying changes in brain reward circuitry persist beyond physical detoxification. Patients remain at high risk for cue-induced relapse even after years of sobriety when exposed to major life stressors or environmental triggers.

• SUD Severity SpecifiersSubstance use disorder requires meeting at least 2 out of 11 diagnostic criteria within a 12-month timeframe.

  • Substance use disorder requires meeting at least 2 out of 11 diagnostic criteria within a 12-month timeframe.
  • Mild severity is specified when a patient meets 2 to 3 diagnostic criteria.
  • Moderate severity is specified when a patient meets 4 to 5 diagnostic criteria.
  • Severe severity is specified when a patient meets 6 or more diagnostic criteria.
  • Early remission applies when no criteria are met, except craving, for at least 3 months but less than 12 months.
  • Sustained remission applies when no criteria are met, except craving, for 12 months or longer.
• Safety AlertPersistent neurocircuitry changes in the mesolimbic dopamine circuit, amygdala, and hippocampus persist beyond physical detoxification, leaving patients vulnerable to rapid relapse when exposed to environmental cues or severe stress.

  • Persistent neurocircuitry changes in the mesolimbic dopamine circuit, amygdala, and hippocampus persist beyond physical detoxification, leaving patients vulnerable to rapid relapse when exposed to environmental cues or severe stress.
• Board TrapDo not select obsolete DSM-IV terms like substance abuse or substance dependence on current board exams. DSM-5-TR uses only substance use disorder with severity specifiers.

  • Do not select obsolete DSM-IV terms like substance abuse or substance dependence on current board exams. DSM-5-TR uses only substance use disorder with severity specifiers.
  • Do not count tolerance or withdrawal toward a substance use disorder diagnosis if the patient is taking prescribed medications under legitimate medical management.
• First-Line ApproachCalculate the exact number of criteria met in the past 12 months to assign the correct severity specifier (mild, moderate, or severe).

  • Calculate the exact number of criteria met in the past 12 months to assign the correct severity specifier (mild, moderate, or severe).
  • Combine evidence-based pharmacotherapy such as acamprosate or naltrexone with structured psychosocial therapies like motivational interviewing and cognitive behavioral therapy.
• B) Mild alcohol use disorderA: Substance abuse is an outdated DSM-IV category that is no longer used in DSM-5-TR.

  • A: Substance abuse is an outdated DSM-IV category that is no longer used in DSM-5-TR.
  • C: Moderate severity requires meeting 4 to 5 criteria.
  • D: Severe severity requires meeting 6 or more criteria.
• B) In early remissionEarly remission is specified when a patient who previously met criteria for a substance use disorder meets no criteria, except craving, for at least 3 months but less than 12 months.

  • Early remission is specified when a patient who previously met criteria for a substance use disorder meets no criteria, except craving, for at least 3 months but less than 12 months.
  • A: Sustained remission requires being criteria-free, except craving, for a minimum of 12 consecutive months.
  • C: In a controlled environment applies only when physical access to the substance is restricted, such as during inpatient hospitalization or incarceration.
  • D: On maintenance therapy applies when the patient is taking prescribed maintenance medications like buprenorphine or methadone.
• C) Severe opioid use disorderA: Mild severity requires 2 to 3 criteria.

  • A: Mild severity requires 2 to 3 criteria.
  • B: Moderate severity requires 4 to 5 criteria.
  • D: Opioid dependence is obsolete DSM-IV terminology.
• Active Recall1. How many criteria must a patient meet within 12 months to diagnose a substance use disorder?

  • 1. How many criteria must a patient meet within 12 months to diagnose a substance use disorder?
  • 2. What is the criterion count range required for a moderate substance use disorder specifier?
  • 3. What is the minimum duration required without criteria, except craving, to specify sustained remission?
  • 4. Which two historical DSM-IV diagnostic terms were combined into substance use disorder in DSM-5-TR?
  • 5. Which single criterion is allowed to persist during both early remission and sustained remission?
• The 'Tempted With Cocaine, Scotch, Rum' MnemonicDiagnosis of substance use disorder under DSM-5-TR requires meeting at least 2 out of 11 diagnostic criteria within a 12-month period.

  • Diagnosis of substance use disorder under DSM-5-TR requires meeting at least 2 out of 11 diagnostic criteria within a 12-month period.
  • The memory tool Tempted With Cocaine, Scotch, Rum maps the 11 criteria into 5 clinical domains: Tolerance, Withdrawal, Control impairment, Social consequences, and Risky use.
  • Severity is coded by symptom count: mild is 2 to 3 criteria, moderate is 4 to 5 criteria, and severe is 6 or more criteria.
  • Remission specifiers require time thresholds: early remission means 3 to 12 months without meeting criteria (except craving), while sustained remission means 12 months or longer.
  • DSM-5-TR eliminated the former DSM-IV distinction between substance abuse and substance dependence, combining them into a single diagnostic continuum.
  • Substance use disorder creates long-lasting neurochemical and structural changes in the mesolimbic dopamine pathway that persist well past acute detoxification.
• Mnemonic Category Breakdown1. Tolerance and Withdrawal (Tempted With)

  • 1. Tolerance and Withdrawal (Tempted With)
  • Tolerance: Needing markedly increased amounts of the substance to achieve intoxication or desired effect, or experiencing a markedly diminished effect with continued use of the same amount.
  • Withdrawal: Experiencing the characteristic physiological withdrawal syndrome for the specific substance, or taking the substance (or a closely related substance) to relieve or avoid withdrawal symptoms.
  • 2. Control Impairment (Cocaine)
  • Using larger amounts of the substance or over a longer period than was originally intended.
  • Persistent desire or unsuccessful efforts to cut down or control substance use.
• Severity and Remission SpecifiersMild: Presence of 2 to 3 symptoms.

  • Mild: Presence of 2 to 3 symptoms.
  • Moderate: Presence of 4 to 5 symptoms.
  • Severe: Presence of 6 or more symptoms.
  • Early Remission: No criteria met for at least 3 months but less than 12 months (with the exception of craving).
  • Sustained Remission: No criteria met at any time during a period of 12 months or longer (with the exception of craving).
  • Additional Specifiers: In a controlled environment (where access to the substance is restricted) and On maintenance therapy (such as agonist or partial agonist therapy for opioid use disorder).
• Clinical Practice SignpostsWhen evaluating a patient for potential substance use disorder, open-ended screening questions (such as "How much alcohol do you drink in a typical week?") combined with motivational interviewing are the initial non-judgmental steps to explore ambivalence and overcome denial.

  • When evaluating a patient for potential substance use disorder, open-ended screening questions (such as "How much alcohol do you drink in a typical week?") combined with motivational interviewing are the initial non-judgmental steps to explore ambivalence and overcome denial.

  Board trap. Confusing substance dependence with physical dependence. Test writers love to present a patient on prescribed maintenance therapy or pain management who exhibits tolerance, then ask for the diagnosis. If there is no compulsive use, loss of control, or social impairment, it is not

  Safety. Physical dependence (tolerance and withdrawal) can occur as a normal physiological adaptation to prescribed medications (such as long-term opioid therapy for pain or benzodiazepines for medical conditions) without the patient having a substance use disorder. Never diagnose a subs

• Definition of a 'Standard Drink'A standard drink in the United States contains 12 g of pure ethanol (0.5 oz of pure alcohol).

  • A standard drink in the United States contains 12 g of pure ethanol (0.5 oz of pure alcohol).
  • Standard drink equivalents include 12 oz of regular beer (5% alcohol), 4 oz of non-fortified wine (12% alcohol), or 1 to 1.5 oz of 80-proof distilled spirits (40% alcohol).
  • The legal blood alcohol concentration (BAC) limit for operating a motor vehicle in the United States is 0.08 g/dL.
  • Binge drinking brings the BAC to 0.08 g/dL or higher, typically requiring 5 or more drinks for men or 4 or more drinks for women within a 2-hour window.
  • Heavy drinking is defined as 2 or more drinks per day for men (14 or more per week) or 1 or more drinks per day for women (7 or more per week).
  • Moderate drinking is defined as 2 or fewer drinks per day for men and 1 or fewer drinks per day for women, while adults over age 65 should consume less than 1 drink per day regardless of gender.
• Standard Drink Equivalents and BAC Parameters12 oz of regular beer (5% alcohol content)

  • 12 oz of regular beer (5% alcohol content)
  • 4 oz of non-fortified wine (12% alcohol content, 24 to 28 proof)
  • 1 to 1.5 oz of liquor or distilled spirits (80 proof or 40% alcohol content)
• Alcohol Drinking PatternsBinge drinking: A acute pattern that elevates BAC to 0.08 g/dL or above within 2 hours. This corresponds to 5 or more standard drinks on a single occasion for men, or 4 or more standard drinks for women.

  • Binge drinking: A acute pattern that elevates BAC to 0.08 g/dL or above within 2 hours. This corresponds to 5 or more standard drinks on a single occasion for men, or 4 or more standard drinks for women.
  • Heavy drinking: A chronic daily pattern defined as 2 or more drinks per day for men, or 1 or more drinks per day for women.
  • Moderate drinking: Daily maintenance defined as 2 or fewer drinks per day for men, or 1 or fewer drinks per day for women.
  • Geriatric threshold: For adults aged 65 and older, recommended consumption drops to less than 1 drink per day for both men and women due to age-related reductions in total body water and decreased hepatic drug metabolism.
• Clinical SignpostsNaltrexone or acamprosate combined with psychosocial counseling serves as first-line pharmacotherapy for moderate to severe alcohol use disorder.

  • Impaired driving at or above a BAC of 0.08 g/dL poses severe safety hazards. If an intoxicated patient insists on driving from the clinic, immediate intervention and law enforcement notification are required to prevent harm.
  • Naltrexone or acamprosate combined with psychosocial counseling serves as first-line pharmacotherapy for moderate to severe alcohol use disorder.

  Board trap. Assuming 1 container equals 1 standard drink. A 24 oz "tall boy" beer equals 2 standard drinks, and high-proof liquor delivers a far denser ethanol load per fluid ounce. Another trap is prescribing naltrexone to a patient with acute hepatitis or liver failure; acamprosate is the

  Safety. Impaired driving at or above a BAC of 0.08 g/dL poses severe safety hazards. If an intoxicated patient insists on driving from the clinic, immediate intervention and law enforcement notification are required to prevent harm.

• Binge Drinking vs. Heavy DrinkingThink: Binge drinking is single-occasion volume; heavy drinking is daily chronic volume.

  • Think: Binge drinking is single-occasion volume; heavy drinking is daily chronic volume.
  • Priority: Binge drinking drives acute intoxication, trauma, and overdose risk. Heavy drinking drives organ damage, macrocytosis, and physical dependence.
  • Boards are testing: Gender-specific thresholds. Binge is 5+ drinks (men) or 4+ drinks (women) in 2 hours. Heavy is 2+ drinks/day (men) or 1+ drink/day (women).
• Naltrexone vs. AcamprosateThink: Naltrexone blocks the reward high; acamprosate balances post-withdrawal brain chemistry.

  • Think: Naltrexone blocks the reward high; acamprosate balances post-withdrawal brain chemistry.
  • Priority: Check liver function and opioid use history before picking a medication.
  • Boards are testing: Clearance pathways. Naltrexone is hepatically metabolized and contraindicated in liver failure or active opioid use. Acamprosate is renally excreted, making it safe in liver disease but contraindicated in severe renal failure.
• Older Adult Drinking GuidelinesOlder adult drinking threshold: For individuals aged 65 and older, national guidelines recommend consuming less than 1 standard drink per day (maximum of 1 drink daily) regardless of gender.

  • Older adult drinking threshold: For individuals aged 65 and older, national guidelines recommend consuming less than 1 standard drink per day (maximum of 1 drink daily) regardless of gender.
  • Standard drink volume: One standard drink contains 12 grams of pure ethanol, equal to 12 ounces of beer, 4 ounces of non-fortified wine, or 1.5 ounces of 80-proof distilled spirits.
  • Adult vs older adult contrast: Under age 65, moderate drinking is up to 2 drinks daily for men and 1 drink daily for women. After age 65, gender differences disappear and the limit drops to less than 1 drink daily for all adults.
  • Under-screening population: Older adults, women, and adolescents represent the three patient groups most frequently under-screened for alcohol use disorder.
  • Physiological vulnerability: Decreased total body water, reduced hepatic metabolism, and heightened central nervous system sensitivity cause older adults to achieve higher blood alcohol concentrations from smaller amounts of alcohol.
  • First-line pharmacotherapy in liver impairment: Acamprosate is the primary choice for maintaining abstinence in older adults or patients with liver disease because it is renally excreted, whereas naltrexone is contraindicated in acute hepatitis or liver failure.
• Core Spoken Teaching: Alcohol Drinking Patterns and Older Adult Guidelines12 ounces of beer

  • 12 ounces of beer
  • 4 ounces of non-fortified wine
  • 1.5 ounces of 80-proof hard liquor
  • Moderate drinking: Up to 2 drinks per day for men, and up to 1 drink per day for women under age 65.
  • Heavy drinking: 2 or more drinks per day for men, or 1 or more drinks per day for women.
  • Binge drinking: Consuming 5 or more drinks for men, or 4 or more drinks for women, on a single occasion within approximately 2 hours, bringing blood alcohol concentration to 0.08 grams per deciliter or higher.
• Older Adult Specific GuidelinesScreen every older adult using open-ended questions. Ask "How much alcohol do you drink?" rather than "Do you drink alcohol?" Older adults, women, and adolescents are the three groups most under-screened in primary and psychiatric care.

  • Test-takers often apply standard gender-based thresholds (2 drinks for men, 1 for women) to elderly vignettes. On board exams, remember that gender distinction drops away after age 65; the limit is less than 1 drink daily for both male and female older adults.
  • Screen every older adult using open-ended questions. Ask "How much alcohol do you drink?" rather than "Do you drink alcohol?" Older adults, women, and adolescents are the three groups most under-screened in primary and psychiatric care.

  Board trap. Test-takers often apply standard gender-based thresholds (2 drinks for men, 1 for women) to elderly vignettes. On board exams, remember that gender distinction drops away after age 65; the limit is less than 1 drink daily for both male and female older adults.

  Safety. Aging reduces total body water volume and hepatic enzyme activity. As a result, an older adult consuming a single drink will achieve a significantly higher blood alcohol concentration and experience greater cognitive and motor impairment than a younger person drinking the same am

• Pharmacotherapy Selection in Older AdultsAcamprosate: First-line agent for maintaining abstinence in patients with liver disease. It restores GABA and glutamate balance and is excreted by the kidneys.

  • Acamprosate: First-line agent for maintaining abstinence in patients with liver disease. It restores GABA and glutamate balance and is excreted by the kidneys.
  • Disulfiram: Aversive agent causing acetaldehyde buildup if alcohol is consumed. Safety alert: It is not initial therapy and is contraindicated in severe cardiac disease, significant hepatic impairment, or cognitive deficits.
• Active Recall Checkpoints1. What is the recommended maximum daily alcohol intake limit for adults aged 65 and older?

  • 1. What is the recommended maximum daily alcohol intake limit for adults aged 65 and older?
  • 2. Which three patient populations are most frequently under-screened for alcohol use disorder?
  • 3. Why is acamprosate preferred over naltrexone in an older adult with alcohol use disorder and elevated liver transaminases?
  • 4. What lab finding on a complete blood count serves as an objective marker for heavy alcohol consumption occurring over 2 to 3 months?
  • 5. How do age-related changes in body composition alter blood alcohol concentration in older adults?
• Denial vs. AnosognosiaDenial is defined as the cognitive defense mechanism where an individual believes a substance use disorder is not causing problems, minimizes negative consequences, or insists that outside treatment is unnecessary.

  • Denial is defined as the cognitive defense mechanism where an individual believes a substance use disorder is not causing problems, minimizes negative consequences, or insists that outside treatment is unnecessary.
  • Anosognosia is a neuro-circuitry failure or organic lack of illness awareness seen in neurological conditions or schizophrenia, whereas denial is a psychological coping strategy used to avoid emotional distress.
  • DSM-5-TR diagnosis of substance use disorder requires 2 or more criteria met within a 12 month period using the mnemonic TEMPTED.
  • Severity is coded as mild with 2 to 3 symptoms, moderate with 4 to 5 symptoms, and severe with 6 or more symptoms.
  • Physical dependence requires physiological tolerance or withdrawal, while substance dependence can occur without physical symptoms.
  • Psychological dependence features intense cravings, a strong desire to use, and taking the drug to avoid low or unpleasant mood states.
• Denial versus AnosognosiaThe first-line intervention for confronting denial is motivational interviewing. Direct confrontation escalates defensiveness and solidifies denial. The PMHNP must utilize open ended questions, validate patient feelings, reflect ambivalence, and support self efficacy.

  • The first-line intervention for confronting denial is motivational interviewing. Direct confrontation escalates defensiveness and solidifies denial. The PMHNP must utilize open ended questions, validate patient feelings, reflect ambivalence, and support self efficacy.

  Board trap. Do not confuse psychological denial with anosognosia. Denial is a psychological defense mechanism where the patient possesses the anatomical capacity for insight but protects the ego by rationalizing or minimizing consequences. Conversely, anosognosia is an anatomical neurologica

  Safety. Denial leads patients to severely underreport substance amounts, delaying essential care and increasing the risk of unmonitored withdrawal seizures or delirium tremens. Always obtain collateral information from family members, case managers, or objective lab markers like AST, ALT

• Tolerance and WithdrawalPhysical dependence is defined by two cardinal physiological features: tolerance (requiring increased doses for the same effect) and withdrawal (substance-specific physical or psychological symptoms upon cessation).

  • Physical dependence is defined by two cardinal physiological features: tolerance (requiring increased doses for the same effect) and withdrawal (substance-specific physical or psychological symptoms upon cessation).
  • Substance dependence can occur with or without physical dependence, as psychological cravings and loss of control drive compulsive use independently.
  • DSM-5-TR criteria require 2 or more of 11 criteria within a 12-month period to diagnose substance use disorder (severity: mild = 2 to 3 symptoms, moderate = 4 to 5 symptoms, severe = 6 or more symptoms).
  • Denial is the primary cognitive defense mechanism in addiction, where the individual minimizes consequences, disavows impairment, or rejects the need for outside treatment.
  • Alcohol withdrawal carries high mortality due to autonomic hyperarousal, delirium tremens, and seizures; first-line pharmacological management utilizes benzodiazepines (such as lorazepam, chlordiazepoxide, or diazepam).
  • Opioid withdrawal presents with severe multi-system autonomic hyperarousal (COWS scale), managed with clonidine for sympathetic surges, buprenorphine or methadone for substitution, and symptom-specific adjuncts.
• Signpost SummaryBenzodiazepines are the first-line intervention for acute alcohol withdrawal to stabilize GABAergic tone and prevent seizures or delirium tremens.

  • Never administer IV glucose prior to thiamin in malnourished or severe alcohol use disorder patients; doing so precipitates acute Wernicke encephalopathy (delirium, ataxia, ophthalmoplegia).
  • Benzodiazepines are the first-line intervention for acute alcohol withdrawal to stabilize GABAergic tone and prevent seizures or delirium tremens.

  Board trap. Assuming that physical dependence alone equals addiction. On board exams, tolerance and withdrawal resulting from prescribed medical therapy (such as pain management or supervised anxiety treatment) do not count toward DSM-5-TR substance use disorder criteria unless accompanied b

  Safety. Never administer IV glucose prior to thiamin in malnourished or severe alcohol use disorder patients; doing so precipitates acute Wernicke encephalopathy (delirium, ataxia, ophthalmoplegia).

• DSM-5-TR Substance Use Disorder CriteriaTolerance: Needing increased amounts for effect or experiencing diminished effect with the same amount.

  • Tolerance: Needing increased amounts for effect or experiencing diminished effect with the same amount.
  • Withdrawal: Characteristic withdrawal syndrome or taking substances to avoid withdrawal.
  • Control loss: Taking larger amounts over longer periods than intended, persistent desire or unsuccessful efforts to cut down, spending excessive time obtaining, using, or recovering, and intense cravings.
  • Social consequences: Failure to fulfill major role obligations at work, school, or home; continued use despite persistent social or interpersonal problems; giving up important activities.
  • Risky use: Recurrent use in physically hazardous situations (such as driving impaired) and continued use despite knowing it causes or worsens physical or psychological problems.
• Substance-Specific Withdrawal PatternsStimulant withdrawal (amphetamines, cocaine): Characterized by dysphoric mood, profound fatigue, vivid unpleasant dreams, hypersomnia or insomnia, increased appetite, and psychomotor retardation or agitation.

  • Stimulant withdrawal (amphetamines, cocaine): Characterized by dysphoric mood, profound fatigue, vivid unpleasant dreams, hypersomnia or insomnia, increased appetite, and psychomotor retardation or agitation.
  • Sedative/Hypnotic withdrawal (benzodiazepines, barbiturates): Mirrors alcohol withdrawal with severe autonomic instability, tremors, anxiety, confusion, and life-threatening seizures.
• Naltrexone (ReVia, Vivitrol)Naltrexone (ReVia, Vivitrol) is a first-line FDA-approved medication for moderate to severe alcohol use disorder to reduce cravings and heavy drinking.

  • Naltrexone (ReVia, Vivitrol) is a first-line FDA-approved medication for moderate to severe alcohol use disorder to reduce cravings and heavy drinking.
  • Mechanism of action: Competitive mu-opioid receptor antagonist that blocks endogenous opioid release triggered by alcohol, preventing the reinforcing euphoria or high.
  • Formulations: Oral naltrexone (ReVia) dosed at 50 mg daily, or long-acting injectable naltrexone (Vivitrol) administered as a 380 mg intramuscular injection every 4 weeks.
  • Strictly contraindicated in patients taking opioids or in acute opioid withdrawal. Patients must be opioid-free for 7 to 10 days prior to initiation to prevent precipitated withdrawal.
  • Strictly contraindicated in acute hepatitis or liver failure. Obtain baseline and periodic liver function tests (AST, ALT) due to dose-dependent hepatotoxicity.
  • Do not confuse naltrexone with naloxone (Narcan). Naloxone is a short-acting emergency antagonist for acute opioid overdose, whereas naltrexone is a long-acting maintenance therapy.

  Board trap. Do not confuse naltrexone with naloxone (Narcan). Naloxone is a short-acting emergency antagonist for acute opioid overdose, whereas naltrexone is a long-acting maintenance therapy.

  Safety. Strictly contraindicated in patients taking opioids or in acute opioid withdrawal. Patients must be opioid-free for 7 to 10 days prior to initiation to prevent precipitated withdrawal.

• Mechanism of Action and Clinical FocusFirst-line agent recommended by national guidelines for moderate to severe alcohol use disorder.

  • First-line agent recommended by national guidelines for moderate to severe alcohol use disorder.
  • Acts as a competitive antagonist at mu-opioid receptors.
  • Blocks the pleasure pathway by preventing endogenous opioids from binding after alcohol consumption.
  • Reduces alcohol cravings and decreases the risk of returning to heavy drinking if a slip occurs.
• Formulations and AdministrationOral formulation: ReVia, prescribed as 50 mg once daily.

  • Oral formulation: ReVia, prescribed as 50 mg once daily.
  • Injectable formulation: Vivitrol, administered as a 380 mg intramuscular gluteal injection once every 4 weeks.
  • Injectable Vivitrol improves medication adherence for patients struggling with daily oral dosing.
• Critical Safety Alerts and ContraindicationsActive opioid use. Administering naltrexone to a patient taking prescribed opioids or using illicit opioids precipitates acute, severe opioid withdrawal.

  • Active opioid use. Administering naltrexone to a patient taking prescribed opioids or using illicit opioids precipitates acute, severe opioid withdrawal.
  • Require a negative urine drug screen and an opioid-free window of 7 to 10 days before starting therapy.
  • If a patient has upcoming surgery or dental procedures requiring opioid analgesia, naltrexone is contraindicated because it blocks opioid pain relief.
  • Active liver disease. Naltrexone is hepatotoxic at high doses and is contraindicated in acute hepatitis or liver failure. Monitor baseline and follow-up LFTs.

  Board trap. If a patient has upcoming surgery or dental procedures requiring opioid analgesia, naltrexone is contraindicated because it blocks opioid pain relief.

  Safety. Active opioid use. Administering naltrexone to a patient taking prescribed opioids or using illicit opioids precipitates acute, severe opioid withdrawal.

• Pharmacotherapy ComparisonsNaltrexone vs Acamprosate: Select naltrexone to reduce active cravings in patients with normal liver function. Select acamprosate in patients with liver impairment, as acamprosate is cleared renally.

  • Naltrexone vs Acamprosate: Select naltrexone to reduce active cravings in patients with normal liver function. Select acamprosate in patients with liver impairment, as acamprosate is cleared renally.
  • Naltrexone vs Disulfiram: Disulfiram (Antabuse) is an aversion agent causing a severe physical reaction when alcohol is consumed. It does not reduce daily cravings and is not first-line initial therapy.
  • Naltrexone vs Naloxone: Naloxone is a short-acting antagonist used exclusively for emergency opioid overdose reversal.
• Disulfiram (Antabuse) SafetyDisulfiram (Antabuse) is an aldehyde dehydrogenase inhibitor used as an aversion therapy, NOT as a first-line agent or initial craving-reduction therapy.

  • Disulfiram (Antabuse) is an aldehyde dehydrogenase inhibitor used as an aversion therapy, NOT as a first-line agent or initial craving-reduction therapy.
  • Combining disulfiram with alcohol produces a toxic buildup of acetaldehyde, causing severe flushing, throbbing headache, nausea, vomiting, tachycardia, and hypotension.
  • Absolute contraindications include severe cardiac disease, psychosis, active seizure disorders, pregnancy, and concurrent use of metronidazole or alcohol-containing products.
  • Disulfiram does NOT reduce physiological alcohol cravings. Naltrexone and acamprosate are first-line FDA-approved agents for craving reduction and relapse prevention.
  • Patients must refrain from all alcohol (including mouthwashes, OTC cough syrups, and hand sanitizers) for at least 12 hours before starting disulfiram and for 14 days after discontinuation.
  • Acamprosate (Campral) is cleared renally and preferred in liver disease, whereas naltrexone (ReVia, Vivitrol) is metabolized by the liver and contraindicated in acute hepatitis or current opioid use.

  Board trap. Disulfiram does NOT reduce physiological alcohol cravings. Naltrexone and acamprosate are first-line FDA-approved agents for craving reduction and relapse prevention.

  Safety. Combining disulfiram with alcohol produces a toxic buildup of acetaldehyde, causing severe flushing, throbbing headache, nausea, vomiting, tachycardia, and hypotension.

• Safety Alerts, Contraindications, and Drug InteractionsBefore prescribing disulfiram, the PMHNP must confirm that the patient is fully motivated, cognitively intact, and completely abstinent from alcohol for at least 12 hours.

  • Before prescribing disulfiram, the PMHNP must confirm that the patient is fully motivated, cognitively intact, and completely abstinent from alcohol for at least 12 hours.
  • Severe cardiac disease: Coronary artery disease, severe hypertension, or heart failure, because severe hypotension and tachycardia during a reaction can be fatal.
  • Severe liver disease: Disulfiram carries a risk of severe hepatotoxicity, requiring baseline and periodic liver function tests.
  • Psychotic disorders: Can precipitate acute psychosis or confusion.
  • Seizure disorders: Lowers the seizure threshold.
  • Concurrent metronidazole: Combining disulfiram with metronidazole can cause acute confusion and psychosis.

  Safety. Before prescribing disulfiram, the PMHNP must confirm that the patient is fully motivated, cognitively intact, and completely abstinent from alcohol for at least 12 hours.

• Compare and Distinguish: Alcohol Dependence PharmacotherapyDisulfiram (Antabuse)

  • Disulfiram (Antabuse)
  • Primary role: Aversion therapy for highly motivated patients seeking complete abstinence.
  • Mechanism: Inhibits aldehyde dehydrogenase, creating toxic acetaldehyde buildup upon alcohol ingestion.
  • Does not reduce cravings.
  • Organ considerations: Risk of hepatotoxicity; requires baseline liver function tests.
  • Key restriction: Must avoid all alcohol for 12 hours before starting and up to 14 days after stopping.

  Board trap. Does not reduce cravings.

  Safety. Strictly contraindicated in patients taking prescription opioids or with acute hepatitis / liver failure. Must be opioid-free for 7 to 10 days prior to initiation.

• ACTA HEALTH & WELLNESS — COMPREHENSIVE HOMEPAGE WRITING BRIEF1. HOMEPAGE PURPOSE.

  • 1. HOMEPAGE PURPOSE.
  • Primary Conversion Goal: Encourage the user to take the first step toward better health by scheduling a secure virtual consultation via our private contact form.
  • Secondary Goals:
  • Direct patients to specialized condition/service pages (ADHD, anxiety, panic, depression, insomnia, OCD, trauma) [artifacts].
  • Provide transparent out-of-network pricing, Superbill billing parameters, and standard CPT codes to reassure financial investment.
  • Educate on our HIPAA-compliant telemental health model and rule out physical medical mimics.
• Service Scope Do / Don t Matrix9. AUDIENCE / PATIENT FIT.

  • 9. AUDIENCE / PATIENT FIT.
  • Ages Served: Teenagers (12-17), college students/young adults, and busy adults across the lifespan [artifacts].
  • Prominent Demographics to Feature:
  • The Safety-Sensitive Shift-Worker: Rig workers, firefighting captains, municipal water operators, and 911 dispatchers who worry that seeking help will lead to suspensions, suspension of credentials, or loss of CDL.
  • The High-Pressure Professional: Medical billing specialists, retail managers, and high school teachers navigating corporate audits, heavy shipping deadlines, or public-facing burnout [artifacts].
  • The Exhausted Caregiver / Parent: Mothers and active partners carrying the entire domestic and emotional weight of the household alone, experiencing physical collapse [artifacts].
• Section 1: Hero Sanctuary (Above the Fold)Purpose: To validate physical distress immediately, establish board-certified authority, and offer secure Louisiana telehealth.

  • Purpose: To validate physical distress immediately, establish board-certified authority, and offer secure Louisiana telehealth.
  • Core Copy Message: *"Settle Your Brain s Alarm: Safe, Private Telehealth and Clean Prescribing in Louisiana"*.
  • Locked Facts to Include: Brooke Bryant, PMHNP-BC; secure Louisiana telehealth; out-of-network Superbill filing.
  • Keyword Targets: *private psychiatric NP Lafayette LA, online medication management Louisiana, telehealth Louisiana mental health*.
  • CTAs & Links: Primary CTA button: *"Schedule Your Secure Virtual Consultation"* $
• Section 2: Somatic-Behavioral ChecklistPurpose: Encourage immediate patient self-recognition of autonomic hyperarousal, muscle tension, and career-stigma boundaries.

  • Purpose: Encourage immediate patient self-recognition of autonomic hyperarousal, muscle tension, and career-stigma boundaries.
  • Core Copy Message: *"Are You Carrying This Heavy Physical Burden? You Might Feel This Way If..."*.
  • Checklist Points:
  • Bedtime panic and waking up at 2:00 AM drenched in cold sweat with your heart racing.
  • Somatic muscle guarding: carrying constant neck stiffness, a clenched jaw, or a physical feeling like a tight "fist in your stomach".
  • Sudden "task freezes" where you sit staring blankly at school folders, spreadsheets, or work logging sheets for hours.
• Section 3: The "Clean Prescribing" and Lab Safety ModelPurpose: Detail our high medical safety standards, intake lab requirements, and safe "clean prescribing" boundaries [12, 263, Stahl].

  • Purpose: Detail our high medical safety standards, intake lab requirements, and safe "clean prescribing" boundaries [12, 263, Stahl].
  • Core Copy Message: *"Meticulous Medical Safety and Clean Prescribing in Acadiana"*.
  • Locked Facts to Include: Complete thyroid, metabolic, and CBC lab panels ordered first to rule out physical mimics; targeting lowest effective doses of modern, non-stiffening supports; strict Wellbutrin safety rule.
  • Keyword Targets: *somatic symptoms of chronic stress, thyroid panic mimics, clean prescribing philosophy*.
  • CTAs & Links: CTA button: *"Learn How Private Telehealth Works"* $
• Section 4: Shared Journeys (Student / Parent / Shift-Worker Carousel)Purpose: Show patient narrative variety, de-catastrophize symptoms, and prove realistic positive outcomes without promising "cures" [Rogers; 232, artifacts].

  • Purpose: Show patient narrative variety, de-catastrophize symptoms, and prove realistic positive outcomes without promising "cures" [Rogers; 232, artifacts].
  • Carousel Concept Stories:
  • Story 1 (The Single Professional / OCD): Megan, a 31-year-old Scott medical billing specialist and evening student, trapped in stove-checking loops and bedtime panic $
  • Story 2 (The Safety-Sensitive Shift-Worker / Panic): Marcus, a 37-year-old Youngsville municipal water plant operator and track coach, waking in cold sweats at 2:00 AM with chest tightness and heart-racing cardiophobia $
  • Story 3 (The High School Teen / School Burnout): Dustin, a 16-year-old Rayne FFA junior and agricultural assistant, experiencing exam task freezes, silent isolation, and mind-blanking $
  • Keyword Targets: *Scott LA billing specialist checking loops, Youngsville municipal shift-work sleep help, Rayne family livestock ranch stress support*.
• Section 5: The Provider Alliance (Provider Bio)Purpose: Establish Brooke s advanced PMHNP board certification and medical training, emphasizing a relationship-based model [Rogers; artifacts].

  • Purpose: Establish Brooke s advanced PMHNP board certification and medical training, emphasizing a relationship-based model [Rogers; artifacts].
  • Core Copy Message: *"Your Partner in Recovery: Brooke Bryant, PMHNP-BC"* [artifacts].
  • Keyword Targets: *private online psychiatric NP Acadiana, telehealth Louisiana mental health, trauma-informed NP Louisiana*.
  • CTAs & Links: CTA button: *"Book Your Secure Virtual Consultation"* $
• Section 6: High-Complexity Billing & Superbill TransparencyPurpose: Reassure patient investment, outline out-of-network claims process, and list coding standards.

  • Purpose: Reassure patient investment, outline out-of-network claims process, and list coding standards.
  • Core Copy Message: *"Clear, Transparent Billing & Superbill Filing Support"*.
  • Locked Facts to Include: Strictly out-of-network practice (does not contract with Medicaid, Medicare, or private insurance); detailed, insurance-compliant Superbills immediately provided; CPT procedure codes listed clearly (99205, 99214, 90833, 90838, 90847).
  • Keyword Targets: *out-of-network psychiatric superbill, high-complexity clinical coding Louisiana*.
  • CTAs & Links: CTA button: *"Review Our Transparent Fee Schedule"* $
• Section 7: FAQs & Get Started GuidePurpose: Directly resolve friction points (career stigma, first-visit anxiety, out-of-network billing) and capture low-intent scroll traffic [Rogers; 114, 891].

  • Purpose: Directly resolve friction points (career stigma, first-visit anxiety, out-of-network billing) and capture low-intent scroll traffic [Rogers; 114, 891].
  • Intake/follow-up FAQ list (CPT code explanation, thyroid panic mimic panel, CDL privacy protection).
  • Simple, 3-step sign-up process (Book consultation, order safety labs, meet from home).
  • PHI Contact form safety warning; non-crisis virtual outpatient limitation footer.
  • Keyword Targets: *first psychiatrist visit guide, how to prepare for first visit, Lafayette mental health clinic near me*.
  • CTAs & Links: Final bold CTA button: *"Take Your First Step: Request Your Virtual Consultation"* $
• COWS (Clinical Opiate Withdrawal Scale)Induction of buprenorphine requires establishing objective, active withdrawal on the COWS scale (typically moderate withdrawal with a score of 8 to 12 or higher) before administering the first dose.

  • Induction of buprenorphine requires establishing objective, active withdrawal on the COWS scale (typically moderate withdrawal with a score of 8 to 12 or higher) before administering the first dose.
  • First-line non-opioid pharmacotherapy for autonomic withdrawal symptoms is clonidine, an alpha-2 adrenergic agonist, combined with targeted non-opioid medications including ondansetron for nausea, loperamide for diarrhea, NSAIDs for body aches, and trazodone for insomnia.
  • Naltrexone is an opioid antagonist used for craving reduction in alcohol and opioid dependence, but it is strictly contraindicated in patients actively taking opioids or scheduled for elective procedures requiring opioid analgesia.
• Assessment and COWS Scoring RulesAdministering buprenorphine or naltrexone prematurely while full mu-opioid agonists are still bound to central receptors triggers precipitated withdrawal. This causes an immediate, severe displacement of full agonists, resulting in intense physical distress.

  • Administering buprenorphine or naltrexone prematurely while full mu-opioid agonists are still bound to central receptors triggers precipitated withdrawal. This causes an immediate, severe displacement of full agonists, resulting in intense physical distress.

  Board trap. Questions frequently present a patient with pupillary dilation and tachycardia to test your ability to differentiate opioid withdrawal from sympathomimetic intoxication. Look for autonomic fluid losses such as lacrimation, rhinorrhea, and diarrhea to confirm opioid withdrawal. Se

  Safety. Administering buprenorphine or naltrexone prematurely while full mu-opioid agonists are still bound to central receptors triggers precipitated withdrawal. This causes an immediate, severe displacement of full agonists, resulting in intense physical distress.

• Keyed letter: BA: Depressed mood, fatigue, vivid dreams, and psychomotor agitation characterize stimulant withdrawal, such as from amphetamines or cocaine.

  • A: Depressed mood, fatigue, vivid dreams, and psychomotor agitation characterize stimulant withdrawal, such as from amphetamines or cocaine.
  • C: Increased heart rate, elevated blood pressure, diaphoresis, hand tremor, agitation, and hallucinations characterize acute alcohol or sedative-hypnotic withdrawal.
  • D: Severe cognitive impairment, ataxia, and nystagmus without autonomic signs indicate acute central nervous system neurotoxicity or sedative intoxication rather than opioid withdrawal.
• Buprenorphine Propertiesbuprenorphine is a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist indicated for opioid use disorder medication-assisted treatment (MAT).

  • buprenorphine is a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist indicated for opioid use disorder medication-assisted treatment (MAT).
  • ceiling effect: buprenorphine demonstrates a ceiling effect on respiratory depression and euphoria, making it safer in overdose compared to full mu-agonists like methadone or morphine.
  • high binding affinity: buprenorphine has higher affinity for mu-opioid receptors than full agonists; giving it while full agonists are active displaces them and causes precipitated withdrawal.
  • COWS initiation threshold: buprenorphine initiation requires active, mild-to-moderate withdrawal with a Clinical Opioid Withdrawal Scale (COWS) score of 11 to 12 or higher.
  • initiation timeline: wait at least 12 to 24 hours after short-acting opioids and 48 to 72 hours after long-acting opioids like methadone before administering buprenorphine.
  • combination formulation: buprenorphine/naloxone (Suboxone) uses a 4:1 ratio; naloxone has minimal sublingual bioavailability but precipitates severe withdrawal if crushed and injected, preventing parenteral misuse.
• Pharmacology and Mechanismpartial agonist: buprenorphine binds mu-opioid receptors as a partial agonist and kappa receptors as an antagonist.

  • partial agonist: buprenorphine binds mu-opioid receptors as a partial agonist and kappa receptors as an antagonist.
  • ceiling effect: maximal respiratory depression and euphoria plateau at therapeutic doses, lowering lethal overdose risk relative to full mu-agonists like methadone.
  • receptor affinity: mu-receptor affinity is extremely strong, tightly occupying receptors and displacing full agonists.
• Initiation Protocols and COWS Scoreprecipitated withdrawal: administering buprenorphine while full agonists occupy mu-receptors rapidly strips full agonists, producing acute, severe withdrawal.

  • precipitated withdrawal: administering buprenorphine while full agonists occupy mu-receptors rapidly strips full agonists, producing acute, severe withdrawal.
  • COWS scoring: assess withdrawal severity using the Clinical Opioid Withdrawal Scale (COWS), which evaluates resting heart rate, sweating, restlessness, pupil size, bone or joint aches, runny nose, tearing, gastrointestinal upset, tremor, yawning, and irritability.
  • COWS score ranges: scores of 5 to 12 indicate mild withdrawal, 13 to 24 moderate withdrawal, 25 to 36 moderately severe withdrawal, and greater than 36 severe withdrawal.
  • timing gate: confirm a COWS score of at least 11 to 12 before the first dose.
  • washout interval: allow 12 to 24 hours after short-acting opioids like heroin or oxycodone, and 48 to 72 hours after long-acting opioids like methadone.
• Formulations and Misuse Deterrencecombination sublingual: buprenorphine/naloxone (Suboxone) combines a 4:1 ratio.

  • combination sublingual: buprenorphine/naloxone (Suboxone) combines a 4:1 ratio.
  • sublingual absorption: naloxone has negligible sublingual absorption, allowing buprenorphine therapeutic action.
  • abuse deterrence: intravenous or intranasal administration activates naloxone, blocking mu-receptors and triggering immediate withdrawal.
  • monotherapy: buprenorphine alone (Subutex) is preferred during pregnancy to protect the fetus from naloxone exposure.
  • depot formulation: subcutaneously injected buprenorphine (Sublocade) provides monthly maintenance after sublingual stabilization.
• First-Line Status and Safety Alertsbuprenorphine/naloxone is a first-line office-based MAT choice for moderate to severe opioid use disorder.

  • buprenorphine/naloxone is a first-line office-based MAT choice for moderate to severe opioid use disorder.
  • verify active withdrawal using COWS prior to initiation to avoid severe precipitated withdrawal.
  • concurrent use of buprenorphine with benzodiazepines or central nervous system depressants increases toxicity and fatal respiratory depression risks.
  • prescribing naltrexone or Vivitrol to a patient who requires opioid pain management for upcoming dental or surgical procedures within 30 days blocks analgesia and causes acute withdrawal.

  Board trap. prescribing naltrexone or Vivitrol to a patient who requires opioid pain management for upcoming dental or surgical procedures within 30 days blocks analgesia and causes acute withdrawal.

  Safety. verify active withdrawal using COWS prior to initiation to avoid severe precipitated withdrawal.

• Opioid Use Disorder MAT Agentsbuprenorphine: partial mu-agonist with ceiling effect, high affinity, office-based prescription, requires active withdrawal (COWS score 11 to 12 or higher) before starting.

  • buprenorphine: partial mu-agonist with ceiling effect, high affinity, office-based prescription, requires active withdrawal (COWS score 11 to 12 or higher) before starting.
  • methadone: full mu-agonist without ceiling effect, high overdose and QT prolongation risk, restricted to federally licensed Opioid Treatment Programs.
  • naltrexone: full mu-antagonist blocking opioid receptors and cravings, available orally or as monthly intramuscular Vivitrol, requires complete detoxification for 7 to 14 days before starting.
• Opioid Withdrawal Adjunctsclonidine: alpha-2 adrenergic agonist for autonomic hyperactivity, tremors, and sweating.

  • clonidine: alpha-2 adrenergic agonist for autonomic hyperactivity, tremors, and sweating.
  • ondansetron: serotonin 5-HT3 receptor antagonist for nausea and vomiting.
  • loperamide: peripheral mu-agonist for diarrhea.
  • trazodone: sedating antidepressant for insomnia.
• Sample Question 1D. None of the above

  • D. None of the above
• Sample Question 3B. Dextroamphetamine

  • B. Dextroamphetamine
• Methadone ConsiderationsMethadone and buprenorphine are first-line standard of care pharmacotherapies for pregnant patients with Opioid Use Disorder (OUD), as abrupt opioid withdrawal triggers fetal distress, uterine contraction, and premature labor.

  • Methadone is a full mu-opioid receptor agonist indicated for Opioid Use Disorder (OUD) maintenance and detoxification, requiring daily administration through federally certified Opioid Treatment Programs (OTPs) under SAMHSA oversight.
  • Methadone causes dose-dependent QTc prolongation and torsades de pointes. Baseline ECG and follow-up monitoring are required, especially at doses exceeding 100 mg daily or when combined with QTc-prolonging psychotropics or antimicrobials.
  • Pharmacokinetics: Long elimination half-life of 24 to 36 hours (up to 55 hours) contrasts with a short analgesic duration of 4 to 8 hours. Tissue accumulation over 3 to 5 days means dose titration must occur slowly to prevent delayed fatal respiratory depression.
  • Methadone and buprenorphine are first-line standard of care pharmacotherapies for pregnant patients with Opioid Use Disorder (OUD), as abrupt opioid withdrawal triggers fetal distress, uterine contraction, and premature labor.
  • Prescribers cannot write an outpatient prescription for methadone to treat Opioid Use Disorder (OUD) in a standard clinic setting. Outpatient prescriptions for methadone are legally restricted to pain management only.
  • Drug Interactions: CYP3A4 and CYP2B6 inducers (e.g., carbamazepine, phenytoin, rifampin) rapidly decrease methadone plasma levels and precipitate acute opioid withdrawal, whereas CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole) increase methadone levels and toxicity risks.

  Board trap. Prescribers cannot write an outpatient prescription for methadone to treat Opioid Use Disorder (OUD) in a standard clinic setting. Outpatient prescriptions for methadone are legally restricted to pain management only.

  Safety. Methadone causes dose-dependent QTc prolongation and torsades de pointes. Baseline ECG and follow-up monitoring are required, especially at doses exceeding 100 mg daily or when combined with QTc-prolonging psychotropics or antimicrobials.

• Mechanism and Agonist ProfileRecognized as a gold-standard first-line maintenance treatment for moderate to severe Opioid Use Disorder (OUD) alongside buprenorphine.

  • What it is: Methadone is a synthetic long-acting full mu-opioid receptor agonist that fully binds and activates mu receptors in the central nervous system, suppressing opioid craving and withdrawal while inducing cross-tolerance to illicit opioids.
  • Recognized as a gold-standard first-line maintenance treatment for moderate to severe Opioid Use Disorder (OUD) alongside buprenorphine.
  • Why boards care: Exams test the functional distinction between full agonists (methadone), partial agonists (buprenorphine), and antagonists (naltrexone).
• Regulatory and Clinical Delivery FrameworkClinical Distinction: Methadone prescribed in standard outpatient practice is legally restricted to pain management, never addiction treatment.

  • Clinical Distinction: Methadone prescribed in standard outpatient practice is legally restricted to pain management, never addiction treatment.

  Board trap. Prescribers cannot write an outpatient prescription for methadone to treat Opioid Use Disorder (OUD) in a standard clinic setting. Under SAMHSA regulations, OUD treatment must occur through a certified Opioid Treatment Program (OTP) with daily directly observed dosing until take-

• Cardiac and Respiratory SafetyMethadone carries a major risk for QTc prolongation and torsades de pointes. A baseline ECG is required prior to initiation, with re-evaluation when doses exceed 100 mg daily or when co-administered with QTc-prolonging psychotropics or antimicrobials.

  • Methadone carries a major risk for QTc prolongation and torsades de pointes. A baseline ECG is required prior to initiation, with re-evaluation when doses exceed 100 mg daily or when co-administered with QTc-prolonging psychotropics or antimicrobials.
  • Toxicity Window: Due to terminal half-life accumulation (24 to 36 hours), steady state takes 3 to 5 days. Increasing doses too rapidly within 1 to 2 days creates a high risk of lethal respiratory depression.

  Safety. Methadone carries a major risk for QTc prolongation and torsades de pointes. A baseline ECG is required prior to initiation, with re-evaluation when doses exceed 100 mg daily or when co-administered with QTc-prolonging psychotropics or antimicrobials.

• Pregnancy and Special PopulationsMethadone is first-line maintenance for pregnant women with Opioid Use Disorder (OUD). Maintenance prevents severe maternal-fetal withdrawal spikes that trigger uterine contractions, miscarriage, or stillbirth.

  • Methadone is first-line maintenance for pregnant women with Opioid Use Disorder (OUD). Maintenance prevents severe maternal-fetal withdrawal spikes that trigger uterine contractions, miscarriage, or stillbirth.
  • Postpartum Expectation: Neonatal Abstinence Syndrome (NAS) is an expected, treatable outcome in infants exposed to methadone in utero and is managed in a specialized neonatal setting.
• Cytochrome P450 Drug InteractionsInducers: Co-administration with CYP3A4 inducers (such as carbamazepine, oxcarbazepine, phenytoin, or rifampin) accelerates methadone clearance, throwing the patient into acute opioid withdrawal.

  • Inducers: Co-administration with CYP3A4 inducers (such as carbamazepine, oxcarbazepine, phenytoin, or rifampin) accelerates methadone clearance, throwing the patient into acute opioid withdrawal.
  • Inhibitors: Co-administration with CYP3A4 inhibitors (such as fluoxetine, fluvoxamine, or azole antifungals) decreases clearance, causing elevated methadone plasma concentrations, excessive sedation, and elevated arrhythmia risk.
• Spoken Teaching: Opioid Assessment and MAT ProtocolsMethadone is a full mu-opioid receptor agonist administered through certified Opioid Treatment Programs (OTPs) that requires no initial withdrawal window before starting.

  • Methadone is a full mu-opioid receptor agonist administered through certified Opioid Treatment Programs (OTPs) that requires no initial withdrawal window before starting.
  • Buprenorphine is a partial mu-opioid receptor agonist that requires a patient to be in active, mild-to-moderate opioid withdrawal (typically a COWS score of 8 to 12) before initiation to prevent precipitating severe acute withdrawal.
  • Naltrexone is a full opioid antagonist available in oral or long-acting monthly injectable (Vivitrol) form that requires a complete opioid-free window of 7 to 14 days prior to administration to avoid precipitating immediate severe withdrawal.
• AST/ALT Ratio SignificanceAST to ALT ratio: An AST greater than ALT (AST:ALT ratio greater than 2:1) within 3 times the upper limit of normal strongly indicates heavy alcohol consumption or alcohol use disorder.

  • AST to ALT ratio: An AST greater than ALT (AST:ALT ratio greater than 2:1) within 3 times the upper limit of normal strongly indicates heavy alcohol consumption or alcohol use disorder.
  • Enzyme resolution timeline: Transaminase elevations (AST and ALT) return to baseline within 1 to 3 months of sustained sobriety.
  • Macrocytosis without anemia: Elevated MCV (greater than 96 fL, such as 105 fL) with normal hemoglobin and hematocrit occurs in 60% of heavy drinkers (3 or more drinks per day in women, 5 or more in men).
  • MCV resolution timeline: Macrocytosis normalizes within 2 to 3 months of sustained sobriety.
  • Isolated hypertriglyceridemia: Elevated triglycerides (such as 325 mg/dL) with relatively normal HDL and LDL resolves within 1 to 2 months of sobriety.
  • First-line AUD pharmacotherapy in liver disease: Acamprosate is cleared by the kidneys and is safe in liver impairment, whereas naltrexone is contraindicated in acute hepatitis or liver failure.
• AST to ALT Ratio SignificanceAssess drinking patterns using the CAGE or AUDIT questionnaire, order baseline liver function tests, and counsel on sobriety.

  • What it is: In heavy alcohol consumption, serum AST is elevated higher than ALT, typically remaining within 2 to 3 times the upper limit of normal (for example, AST 83 U/L vs ALT 50 U/L, where normal is 0 to 40 U/L).
  • Why boards care: Exams test your ability to differentiate alcohol-induced hepatic stress from primary viral hepatitis based on enzyme patterns and ratios.
  • An AST value higher than ALT with levels up to 3 times the upper limit of normal points to alcohol. Conversely, ALT higher than AST points toward viral hepatitis.
  • Typical board clue: A middle-aged or young adult with an AST of 83 U/L and ALT of 50 U/L who presents with social or academic decline.
  • Assess drinking patterns using the CAGE or AUDIT questionnaire, order baseline liver function tests, and counsel on sobriety.
  • When the answer changes: If the patient has co-existing liver failure or acute hepatitis, naltrexone becomes contraindicated, making acamprosate the first-line pharmacotherapy.

  Board trap. Mistaking mild transaminase elevation (AST 83 U/L, ALT 50 U/L) for acute viral hepatitis and ordering invasive workups instead of taking a thorough substance history.

  Safety. Never start naltrexone in patients with active liver failure, acute hepatitis, or ongoing opioid use.

• Macrocytosis and Lipid Markers in AUDWhat it is: Mild macrocytosis (MCV greater than 96 fL, such as 105 fL) without anemia (normal hemoglobin 15 g/dL and hematocrit 45%), along with isolated hypertriglyceridemia (triglycerides 325 mg/dL).

  • What it is: Mild macrocytosis (MCV greater than 96 fL, such as 105 fL) without anemia (normal hemoglobin 15 g/dL and hematocrit 45%), along with isolated hypertriglyceridemia (triglycerides 325 mg/dL).
  • Why boards care: These objective laboratory findings serve as covert biological markers for chronic heavy alcohol use when a patient minimizes intake or is in denial.
  • Transaminases resolve in 1 to 3 months of sobriety, macrocytosis resolves in 2 to 3 months of sobriety, and hypertriglyceridemia resolves in 1 to 2 months of sobriety.
  • Fast memory hook: Remember the lab recovery order: Triglycerides normalize fastest (1 to 2 months), transaminases next (1 to 3 months), and red blood cell size last (2 to 3 months due to RBC lifespan).
• Alcohol-Induced Liver Strain vs. Viral HepatitisDo not confuse: Alcohol-related enzyme changes show AST greater than ALT, whereas viral hepatitis shows ALT greater than AST.

  • Do not confuse: Alcohol-related enzyme changes show AST greater than ALT, whereas viral hepatitis shows ALT greater than AST.
  • Think Alcohol when: AST is higher than ALT and both are mildly elevated (under 3 times normal limits), accompanied by elevated MCV or triglycerides.
  • Think Viral Hepatitis when: ALT is significantly higher than AST, often reaching hundreds or thousands of units per liter.
  • Priority difference: Alcohol-induced elevations require substance assessment and lifestyle intervention; acute viral hepatitis requires infectious disease workup and hepatic monitoring.
  • What boards are testing: Recognizing that the "L" in ALT stands for primary Liver/hepatitis injury, while AST predominates in alcohol toxicity.
  • Classic distractor: Ordering viral hepatitis serologies for a mild AST 83 U/L / ALT 50 U/L elevation without first asking about daily beer consumption.
• MCV and MacrocytosisMild macrocytosis without anemia develops in approximately 60% of individuals who consume heavy amounts of alcohol, defined as 3 or more drinks per day for women and 5 or more drinks per day for men.

  • Mild macrocytosis without anemia develops in approximately 60% of individuals who consume heavy amounts of alcohol, defined as 3 or more drinks per day for women and 5 or more drinks per day for men.
  • A classic lab profile presents an elevated mean corpuscular volume (MCV) of 105 fL (normal reference range 80 to 96 fL) alongside a completely normal hemoglobin of 15 g/dL and normal hematocrit of 45%.
  • Macrocytosis resolves within 2 to 3 months of complete sobriety, matching the 120-day lifespan and turnover rate of circulating red blood cells.
  • Isolated hypertriglyceridemia presents with markedly elevated triglycerides (e.g., 325 mg/dL; desirable goal 150 mg/dL or less) despite near-normal HDL (58 mg/dL) and LDL (120 mg/dL), resolving fastest within 1 to 2 months of sobriety.
  • Objective blood markers (MCV, AST, ALT, and triglycerides) provide essential clinical evidence to detect chronic heavy drinking and monitor longitudinal sobriety when patients exhibit denial or underreport consumption.
  • Acamprosate is the first-line pharmacotherapy for maintaining abstinence in patients with alcohol use disorder and co-occurring moderate-to-severe liver disease, because it is excreted by the kidneys, unlike naltrexone which is contraindicated in liver failure or acute hepatitis.
• First-LineOrder a baseline complete blood count, hepatic panel, and lipid panel during initial psychiatric assessment when alcohol misuse is suspected, and use serial MCV and transaminase levels during follow-up to objectively verify reported sobriety. For pharmacotherapy, acamprosate or n

  • For pharmacotherapy, **acamprosate** or **naltrexone** are first-line agents for moderate-to-severe **alcohol use disorder**, with **acamprosate** chosen if the patient has liver disease or requires opioid medications.
• Wernicke-Korsakoff SyndromeWernicke encephalopathy is an acute, reversible neurological emergency caused by severe thiamine (vitamin B1) deficiency, presenting with the classic triad of delirium, ataxia, and ophthalmoplegia.

  • Wernicke encephalopathy is an acute, reversible neurological emergency caused by severe thiamine (vitamin B1) deficiency, presenting with the classic triad of delirium, ataxia, and ophthalmoplegia.
  • Korsakoff psychosis (alcohol amnesic disorder) is a chronic, irreversible neurological condition resulting from inadequately treated Wernicke encephalopathy, characterized by retrograde and anterograde amnesia, confabulation, and lack of insight.
  • First-line intervention for acute alcohol withdrawal or suspected Wernicke encephalopathy requires administering parenteral thiamine prior to or concurrently with intravenous glucose to prevent precipitating or worsening encephalopathy.
  • Chronic heavy alcohol consumption contributes to long-term physical damage across nearly every body system, including major neurocognitive disorder, peripheral neuropathy, cardiomyopathy, cirrhosis, gastritis, GI bleeding, and elevated cancer risk.
  • Administering glucose without thiamine in a thiamine deficient patient depletes remaining thiamine stores during carbohydrate metabolism, which can trigger irreversible neurological destruction.
  • Confusing confabulation in Korsakoff syndrome with intentional lying or malingering; confabulation is an unconscious fabrication of memories to fill memory gaps.

  Board trap. Confusing confabulation in Korsakoff syndrome with intentional lying or malingering; confabulation is an unconscious fabrication of memories to fill memory gaps.

  Safety. Administering glucose without thiamine in a thiamine deficient patient depletes remaining thiamine stores during carbohydrate metabolism, which can trigger irreversible neurological destruction.

• Wernicke EncephalopathyWhat it is: An acute, life-threatening, reversible neuro-psychiatric syndrome resulting from severe thiamine (vitamin B1) depletion caused by chronic alcohol misuse and poor intestinal nutrient absorption.

  • What it is: An acute, life-threatening, reversible neuro-psychiatric syndrome resulting from severe thiamine (vitamin B1) depletion caused by chronic alcohol misuse and poor intestinal nutrient absorption.
  • Classic triad: delirium (confusion and altered mental status), ataxia (gait imbalance and unsteadiness), and ophthalmoplegia (nystagmus and ocular motor nerve paralysis).
  • First-line treatment: Immediate high-dose parenteral thiamine supplementation.
  • Never delay thiamine administration while awaiting lab results in patients with alcohol use disorder presenting with confusion, unsteady gait, or abnormal eye movements.

  Safety. Never delay thiamine administration while awaiting lab results in patients with alcohol use disorder presenting with confusion, unsteady gait, or abnormal eye movements.

• Korsakoff PsychosisWhat it is: A chronic, persistent, largely irreversible neurocognitive disorder (alcohol amnesic disorder) arising as the late sequela of uncorrected or improperly treated Wernicke encephalopathy.

  • What it is: A chronic, persistent, largely irreversible neurocognitive disorder (alcohol amnesic disorder) arising as the late sequela of uncorrected or improperly treated Wernicke encephalopathy.
  • Cardinal features: Severe anterograde amnesia (inability to form new memories) and retrograde amnesia (loss of past memories), accompanied by profound confabulation and intact immediate recall.
  • Confabulation mechanism: The patient spontaneously creates plausible but false stories to cover blank spots in memory without intentional deceit or conscious awareness of lying.
  • Prognosis: Poor recovery rate once structural brain damage occurs in the diencephalon; treatment focuses on long-term abstinence, high-dose thiamine maintenance, and a supportive cognitive environment.
• Long-Term Physical Effects of AlcoholCardiovascular system: Causes persistent hypertension, coronary heart disease, and alcoholic cardiomyopathy.

  • Cardiovascular system: Causes persistent hypertension, coronary heart disease, and alcoholic cardiomyopathy.
  • Gastrointestinal system: Promotes cirrhosis, gastritis, alcoholic hepatitis, upper GI bleeding, and esophageal varices. Intestinal mucosal damage leads to severe malabsorption of vital nutrients, particularly vitamin B12 and thiamine.
  • Oncology and neoplasm risks: Increases cancer incidence across multiple sites, including the mouth, pharynx, esophagus, liver, pancreas, colon, rectum, prostate, ovaries, endometrium, bladder, and breast in women.
  • Psychiatric comorbidity: High rates of comorbid depression, anxiety, and elevated suicide risk.
  • Fetal alcohol spectrum: Maternal alcohol consumption during pregnancy leads to fetal alcohol syndrome and low birth weight.
• Laboratory Findings in Alcohol MisuseLiver transaminases: An AST greater than ALT ratio, usually within 3 times the upper limit of normal (for example, AST of 83 U/L and ALT of 50 U/L when the normal range is 0 to 40 U/L). This ratio resolves within 1 to 3 months of sustained sobriety.

  • Liver transaminases: An AST greater than ALT ratio, usually within 3 times the upper limit of normal (for example, AST of 83 U/L and ALT of 50 U/L when the normal range is 0 to 40 U/L). This ratio resolves within 1 to 3 months of sustained sobriety.
  • Triglycerides: Isolated hypertriglyceridemia (for example, triglycerides of 325 mg/dL with a desirable level of 150 mg/dL or less) with normal HDL and LDL, resolving within 1 to 2 months of sobriety.
• Wernicke Encephalopathy vs. Korsakoff PsychosisDo not confuse: Acute reversible neurological emergency versus chronic irreversible neurocognitive syndrome.

  • Do not confuse: Acute reversible neurological emergency versus chronic irreversible neurocognitive syndrome.
  • Think Wernicke encephalopathy when: Patient presents with the acute triad of delirium, ataxia, and ophthalmoplegia.
  • Think Korsakoff psychosis when: Patient presents with chronic anterograde amnesia, confabulation, and apathy following chronic alcohol misuse.
  • Priority difference: Wernicke encephalopathy requires urgent parenteral thiamine before glucose to halt progression; Korsakoff psychosis requires long-term safety, cognitive support, and harm reduction because structural brain damage has already occurred.
  • What boards are testing: Recognizing the mandatory administration order (thiamine before glucose) and identifying confabulation as an unconscious defense mechanism rather than deliberate deception.
  • Classic distractor: Giving IV dextrose first in an intoxicated, confused patient before administering thiamine.
• B) Administer high-dose parenteral thiamine prior to starting the dextrose infusionA: Giving IV dextrose without thiamine exacerbates thiamine depletion and worsens acute neurological damage.

  • A: Giving IV dextrose without thiamine exacerbates thiamine depletion and worsens acute neurological damage.
  • B: Correct choice.
  • C: Delaying thiamine for neuroimaging risks irreversible progression to Korsakoff psychosis.
  • D: Benzodiazepines treat alcohol withdrawal tremors or seizures but do not correct the underlying thiamine deficiency causing Wernicke encephalopathy.
• B) ConfabulationA: Malingering involves conscious, intentional fabrication of symptoms for primary gain, unlike unconscious confabulation.

  • A: Malingering involves conscious, intentional fabrication of symptoms for primary gain, unlike unconscious confabulation.
  • B: Correct choice.
  • C: Persecutory delusions are fixed false beliefs that others are out to harm the patient, not memory gap filling narratives.
  • D: Delirium tremens presents with autonomic hyperarousal, severe tremors, fever, and vivid hallucinations, not calm memory gap filling.
• B) The transaminase ratio and MCV will resolve within 1 to 3 months of total sobrietyA: Alcohol-induced macrocytosis is reversible upon cessation of drinking and is not permanent bone marrow damage.

  • A: Alcohol-induced macrocytosis is reversible upon cessation of drinking and is not permanent bone marrow damage.
  • B: Correct choice.
  • C: An ALT greater than AST ratio suggests viral hepatitis, whereas AST greater than ALT points to alcohol etiology; biopsy is not initial protocol.
  • D: MCV and transaminase elevations reflect hematologic and hepatic effects of heavy drinking, not neurological Korsakoff psychosis.
• D) Prior history of delirium tremensA: A CIWA score of 10 represents mild withdrawal and alone does not mandate inpatient hospitalization.

  • A: A CIWA score of 10 represents mild withdrawal and alone does not mandate inpatient hospitalization.
  • B: Duration of alcohol use alone is less predictive of life-threatening withdrawal than a past history of delirium tremens.
  • C: Mild tremors can be safely managed in outpatient or partial settings if severe withdrawal history is absent.
  • D: Correct choice.
• Fetal Alcohol Syndrome (FAS)Fetal alcohol syndrome (FAS) is the leading preventable cause of birth defects and neurodevelopmental impairment, caused by in utero exposure to alcohol.

  • Fetal alcohol syndrome (FAS) is the leading preventable cause of birth defects and neurodevelopmental impairment, caused by in utero exposure to alcohol.
  • Zero alcohol consumption during pregnancy is the national standard of care because no safe trimester, threshold, or quantity of alcohol consumption exists.
  • Chronic moderate to heavy alcohol consumption contributes to long-term pathology across every body system, including major neurocognitive disorder, hypertension, cardiomyopathy, cirrhosis, esophageal varices, and peripheral neuropathy.
  • Alcohol is a established carcinogen that increases the risk of breast cancer in women, as well as cancers of the mouth, oropharynx, esophagus, liver, pancreas, colon, and rectum.
  • Lab markers of heavy alcohol use include macrocytosis (MCV greater than 96 fL, typically around 105 fL) without anemia in 60% of heavy drinkers, and an AST to ALT ratio greater than 2 to 1.
  • Acute alcohol detoxification requires administering thiamine (vitamin B1) before any glucose infusion to prevent Wernicke encephalopathy and Korsakoff psychosis.
• Prenatal Exposure and Fetal Alcohol SyndromeThe first-line intervention for pregnant individuals screened positive for alcohol use is immediate motivational interviewing, psychoeducation regarding zero-tolerance pregnancy standards, and rapid referral to perinatal substance use recovery services.

  • The first-line intervention for pregnant individuals screened positive for alcohol use is immediate motivational interviewing, psychoeducation regarding zero-tolerance pregnancy standards, and rapid referral to perinatal substance use recovery services.

  Board trap. Exam items may present a pregnant patient with alcohol dependence and tempt you to choose disulfiram or naltrexone. Naltrexone carries risks of precipitating opioid withdrawal if co-ingested and requires careful risk-benefit balance, while disulfiram is contraindicated due to tox

  Safety. Prenatal alcohol intake is the primary preventable cause of intellectual disability and structural birth defects. When evaluating pregnant women or individuals of childbearing age with alcohol use disorder, immediate screening, harm reduction, and complete abstinence planning are

• Systemic Long-Term Physical ComplicationsNeurologic system: Chronic exposure causes major neurocognitive disorder (alcohol-induced dementia), stroke, peripheral neuropathy (presenting as lower extremity burning pain and numbness), myopathy, and epilepsy from chronic neurotoxicity and nutritional depletion.

  • Neurologic system: Chronic exposure causes major neurocognitive disorder (alcohol-induced dementia), stroke, peripheral neuropathy (presenting as lower extremity burning pain and numbness), myopathy, and epilepsy from chronic neurotoxicity and nutritional depletion.
  • Cardiovascular system: Long-term use drives hypertension, coronary heart disease, and alcoholic cardiomyopathy.
  • Neoplasms: Alcohol significantly elevates malignant disease risk, including breast cancer in women, alongside cancers of the oral cavity, pharynx, esophagus, liver, pancreas, colon, rectum, prostate, and bladder.
  • Psychiatric comorbidity: Severe alcohol use disorder strongly correlates with co-occurring major depressive disorder, anxiety disorders, and a heightened risk of suicide.
• Motivational Interviewing (MI) PrinciplesMotivational interviewing core goal: First-line psychotherapy approach in substance use disorders to explore ambivalence, reduce resistance, and elicit internal motivation for change.

  • Motivational interviewing core goal: First-line psychotherapy approach in substance use disorders to explore ambivalence, reduce resistance, and elicit internal motivation for change.
  • Prochaska precontemplation stage: Patient is in denial with zero recognition of a problem; PMHNP uses non-judgmental reflective listening and supportive empathy to build rapport.
  • Prochaska contemplation stage: Patient acknowledges problem but feels ambivalent; PMHNP guides discussion of pros and cons of substance use versus sobriety.
  • OARS communication framework: Open-ended questions, affirmations, reflective listening, and summaries form the foundation of non-confrontational engagement.
  • Diagnostic criteria threshold: Substance use disorder requires 2 or more of 11 criteria within 12 months (2 to 3 = mild, 4 to 5 = moderate, 6 or more = severe).
  • Billing requirement: Motivational interviewing counseling sessions exceeding 16 minutes can be billed alongside routine medication management appointments.
• Core Principles and Clinical ExecutionFirst-line communication strategies rely on the OARS framework:

  • First-line communication strategies rely on the OARS framework:
  • Open-ended questions that encourage patients to elaborate on their experiences.
  • Affirmations that recognize patient strengths and past successes.
  • Reflective listening that restates feelings and ambivalence back to the patient.
  • Summaries that tie together patient statements and highlight internal change talk.
• PrecontemplationThink: Patient sees no problem and remains in denial.

  • Think: Patient sees no problem and remains in denial.
  • Priority: Build therapeutic alliance and deliver non-judgmental reflective statements.
  • Boards are testing: Avoiding premature push for action or confrontation.
• ContemplationThink: Patient recognizes consequences but feels torn about quitting.

  • Think: Patient recognizes consequences but feels torn about quitting.
  • Priority: Explore pros and cons of continued use versus sobriety.
  • Boards are testing: Drawing out the patient's own arguments for change.
• Preparation and ActionThink: Patient commits to change and seeks an active plan.

  • Think: Patient commits to change and seeks an active plan.
  • Priority: Select specific modalities, set dates, and discuss pharmacotherapy options like acamprosate or naltrexone.
  • Boards are testing: Choosing concrete, structured interventions.
• Key Board Traps and Safety AlertsConfronting active drug-using peers for closure.

  • Confronting active drug-using peers for closure.
  • Premature confrontation during severe denial.

  Board trap. Confronting active drug-using peers for closure.

  Safety. Premature confrontation during severe denial.

• Reflective Listening vs. Direct ConfrontationDo not confuse: Empathetic validation with agreeing with harmful behavior.

  • Do not confuse: Empathetic validation with agreeing with harmful behavior.
  • Think reflective listening when: Patient expresses ambivalence or denial regarding substance use.
  • Think direct confrontation when: Never on board exams; direct confrontation causes resistance.
  • Priority difference: Reflective listening builds trust and elicits change talk; confrontation destroys alliance.
  • What boards are really testing: Ability to respond with advanced practice therapeutic communication rather than judgmental lecturing.
• Precontemplation vs. Contemplation InterventionsDo not confuse: Strategy for a patient who sees no problem with one who is on the fence.

  • Do not confuse: Strategy for a patient who sees no problem with one who is on the fence.
  • Think precontemplation when: Patient blames external factors like law school, advisor, or family for substance-related consequences.
  • Think contemplation when: Patient states "I know I should stop, but drinking helps me sleep."
  • Priority difference: Precontemplation requires rapport building and reflection; contemplation requires exploring pros and cons.
  • What boards are really testing: Selecting stage-matched psychotherapy techniques.
• D) DenialA: Enabling occurs when family members or friends protect the individual from the natural consequences of their substance use.

  • A: Enabling occurs when family members or friends protect the individual from the natural consequences of their substance use.
  • B: Projection involves attributing one's own unacknowledged, unacceptable feelings or impulses onto another person.
  • C: Psychological dependence is characterized by intense cravings, emotional desire to use, or using substances to manage unpleasant mood states.
• A) Relaxing is important to you after you've worked hard at schoolB: Asking a closed-ended question about his DUI directly challenges the patient, increasing resistance and provoking defensiveness.

  • B: Asking a closed-ended question about his DUI directly challenges the patient, increasing resistance and provoking defensiveness.
  • C: Referring back to the advisor's opinion externalizes the issue and creates an "us versus them" dynamic that harms rapport.
  • D: Using a challenging or sarcastic question provokes argument and shuts down collaborative exploration of change.
• B) Confront drug using peers for closureA: Relaxation techniques help manage stress and autonomic hyperarousal associated with intense cravings.

  • A: Relaxation techniques help manage stress and autonomic hyperarousal associated with intense cravings.
  • C: Social skills training provides behavioral tools to refuse substances and manage interpersonal pressure safely.
  • D: Offering positive feedback reinforces progress and builds self-efficacy, helping maintain engagement even after a slip.
• Board Trap: 'Compliance' vs 'Adherence'Compliance implies passive patient submission to provider authority, whereas adherence reflects a collaborative partnership achieved through motivational interviewing.

  • Compliance implies passive patient submission to provider authority, whereas adherence reflects a collaborative partnership achieved through motivational interviewing.
  • Denial is a primary cognitive defense mechanism where a patient minimizes substance consequences or denies needing help, such as drinking six beers nightly while blaming academic failure on outside sources.
  • First-line communication for addressing ambivalence and denial is motivational interviewing, utilizing reflective listening and empathy rather than direct confrontation.
  • Acamprosate is the first-line craving reduction agent for patients with moderate to severe liver disease because it is excreted renally, unlike naltrexone which carries a risk of hepatotoxicity.
  • Naltrexone blocks endogenous opioid receptors to reduce alcohol cravings, but it is strictly contraindicated in patients taking opioids or expecting upcoming surgical pain management within one month.
  • Disulfiram is an aversion therapy causing a severe aldehyde reaction with alcohol, but it is not initial therapy and is contraindicated with concurrent metronidazole use.
• Core Teaching: Compliance, Adherence, and Management StrategiesThe first-line intervention for exploring ambivalence and building rapport in substance use disorders is motivational interviewing. Clinicians must meet patients at their current stage of change (pre-contemplation, contemplation, preparation, action, or maintenance) rather than f

  • **Board trap**: Test writers frequently try to trick candidates into choosing authoritative, confrontational, or scolding responses when a patient displays **denial** or poor treatment participation.
  • Framing patient behavior as non-compliant leads clinicians to force compliance through direct confrontation, which escalates resistance and destroys the therapeutic alliance.
  • On board exams, direct confrontation is always a distractor.
  • The correct approach is **motivational interviewing**, which uses open-ended questions, affirmations, reflective listening, and summarizing to explore ambivalence.

  Board trap. Test writers frequently try to trick candidates into choosing authoritative, confrontational, or scolding responses when a patient displays denial or poor treatment participation. Framing patient behavior as non-compliant leads clinicians to force compliance through direct confro

  Safety. Provider prescribing choices must account for co-occurring physical disease and medical procedures. For alcohol use disorder craving management, naltrexone is contraindicated in acute hepatitis or liver failure, as well as in patients taking opioids or anticipating opioid adminis

• Spoken Teaching ReviewAcamprosate restores GABA and glutamate balance to maintain abstinence. It is excreted mainly by the kidneys, making it safe in liver disease, but requires dose adjustment in renal insufficiency.

  • Acamprosate restores GABA and glutamate balance to maintain abstinence. It is excreted mainly by the kidneys, making it safe in liver disease, but requires dose adjustment in renal insufficiency.
  • Naltrexone blocks endogenous opioid release to decrease the alcohol high and cravings. It is available as a daily oral tablet or a monthly long-acting injection (Vivitrol). It is contraindicated in acute hepatitis, liver failure, or concurrent opioid use.
  • Disulfiram inhibits aldehyde dehydrogenase to cause an aversion reaction (nausea, flushing, tachycardia) if alcohol is consumed. It is not initial therapy and is contraindicated with metronidazole or hidden alcohol sources.
  • Patient safety guidance: Patients should be counseled to avoid drug-using peers and drug cues rather than confronting former drug-using peers for closure, which increases relapse risk.
• Review Question: Denial DefinitionSubstance dependence can occur with or without physical dependence.

  • Substance dependence can occur with or without physical dependence.
  • Physical dependence requires demonstrated physiological tolerance or withdrawal.
  • Psychological dependence involves emotional cravings and using a substance to avoid unpleasant mood states.
  • Denial is a primary cognitive defense mechanism where patients minimize consequences, claim substance use causes no impairment, or refuse outside help.
  • CAGE questionnaire uses 2 or more positive responses (sensitivity 93%, specificity 76%) to screen for problematic drinking and withdrawal risk.
  • AUDIT questionnaire uses 10 items to identify problem drinking before withdrawal develops, especially in college students, women, and minorities.
• Definitions of Dependence and DenialSubstance dependence: Repeated chemical or drug use where physical dependence may be absent or present.

  • Substance dependence: Repeated chemical or drug use where physical dependence may be absent or present.
  • Physical dependence: Characterized by physiological tolerance (needing increased amounts to achieve desired effect) and withdrawal symptoms upon stopping.
  • Psychological dependence: Characterized by compulsive craving, strong desire to use, and taking the drug to escape low or unpleasant mood states.
  • Denial: A core cognitive defense mechanism where the patient believes substance use causes no disruption, minimizes usage, or insists outside treatment is unnecessary.
• Clinical Assessment and ScreeningFirst-Line screening approach: Ask open-ended questions like "How much alcohol do you drink?" instead of closed yes or no items, because patients in denial frequently underreport consumption.

  • First-Line screening approach: Ask open-ended questions like "How much alcohol do you drink?" instead of closed yes or no items, because patients in denial frequently underreport consumption.
  • Collateral information: Obtain history from family members or case managers to establish accurate quantity and frequency.
  • CAGE questionnaire: 4 items assessing Cut down, Annoyed, Guilty, and Eye-opener. 2 or more positive answers indicate problematic drinking with 93% sensitivity and 76% specificity.
  • AUDIT questionnaire: 10 items useful for detecting problem drinking in college students, women, and minorities before physical withdrawal occurs.
• Signposts and Exam PearlsUse motivational interviewing to explore ambivalence, validate feelings, and reflect patient statements out loud to build rapport and foster internal motivation.

  • Denial blinds patients to severe physical and legal risks, such as driving while impaired or failing academic programs. Always assess immediate physical safety, suicidal ideation, and domestic safety during evaluations.
  • Do not confront a patient in denial directly or argue about their substance use. Direct confrontation increases resistance and destroys the therapeutic alliance.
  • Use motivational interviewing to explore ambivalence, validate feelings, and reflect patient statements out loud to build rapport and foster internal motivation.

  Board trap. Do not confront a patient in denial directly or argue about their substance use. Direct confrontation increases resistance and destroys the therapeutic alliance.

  Safety. Denial blinds patients to severe physical and legal risks, such as driving while impaired or failing academic programs. Always assess immediate physical safety, suicidal ideation, and domestic safety during evaluations.

• Review Question: Lab InterpretationAST is elevated greater than ALT, typically within 3 times the upper limit of normal (for example, AST 83 U/L and ALT 50 U/L with normal range 0 to 40 U/L). This ratio resolves within 1 to 3 months of abstinence.

  • AST is elevated greater than ALT, typically within 3 times the upper limit of normal (for example, AST 83 U/L and ALT 50 U/L with normal range 0 to 40 U/L). This ratio resolves within 1 to 3 months of abstinence.
  • Mild macrocytosis (elevated MCV, such as 105 fL with normal 80 to 96 fL) without anemia develops in 60% of heavy drinkers (3 or more drinks daily for women, 5 or more drinks daily for men) and resolves within 2 to 3 months of sobriety.
  • Isolated hypertriglyceridemia (triglycerides 325 mg/dL with normal target 150 mg/dL or less) occurs without severe cholesterol elevation and resolves within 1 to 2 months of abstinence.
  • Acamprosate is the first-line choice for relapse prevention in patients with liver disease because it is excreted renally, whereas naltrexone is contraindicated in acute hepatitis or liver failure.
  • Naltrexone blocks endogenous and exogenous opioids. It is contraindicated in patients requiring opioid analgesia for scheduled procedures or dental surgery.
  • The legal blood alcohol concentration limit for operating a motor vehicle in the United States is 0.08 g/dL, which is typically reached after binge drinking 4 or more drinks for women or 5 or more drinks for men within 2 hours.
• Clinical Interpretation of Hepatic EnzymesDo not confuse alcohol-induced transaminase elevation with viral or non-alcoholic liver disease. In viral hepatitis or non-alcoholic fatty liver disease, ALT is greater than AST. When AST exceeds ALT, think alcohol, statin use, or acetaminophen.

  • Do not confuse alcohol-induced transaminase elevation with viral or non-alcoholic liver disease. In viral hepatitis or non-alcoholic fatty liver disease, ALT is greater than AST. When AST exceeds ALT, think alcohol, statin use, or acetaminophen.

  Board trap. Do not confuse alcohol-induced transaminase elevation with viral or non-alcoholic liver disease. In viral hepatitis or non-alcoholic fatty liver disease, ALT is greater than AST. When AST exceeds ALT, think alcohol, statin use, or acetaminophen.

• Integrating Lab Findings into Relapse PreventionFirst-line treatment for a patient with elevated transaminases or established liver disease is acamprosate, which acts on GABA and glutamate pathways and is excreted by the kidneys.

  • First-line treatment for a patient with elevated transaminases or established liver disease is acamprosate, which acts on GABA and glutamate pathways and is excreted by the kidneys.
  • Naltrexone reduces alcohol cravings by blocking endogenous opioids, but it carries a Safety alert because it is contraindicated in acute hepatitis, liver failure, or in patients taking prescribed opioids.